New screening methodology for selection of polymeric materials for transdermal drug delivery devices by Falcone, Roberto P.
New Jersey Institute of Technology 
Digital Commons @ NJIT 
Dissertations Electronic Theses and Dissertations 
Spring 5-31-2015 
New screening methodology for selection of polymeric materials 
for transdermal drug delivery devices 
Roberto P. Falcone 
New Jersey Institute of Technology 
Follow this and additional works at: https://digitalcommons.njit.edu/dissertations 
 Part of the Materials Science and Engineering Commons 
Recommended Citation 
Falcone, Roberto P., "New screening methodology for selection of polymeric materials for transdermal 
drug delivery devices" (2015). Dissertations. 116. 
https://digitalcommons.njit.edu/dissertations/116 
This Dissertation is brought to you for free and open access by the Electronic Theses and Dissertations at Digital 
Commons @ NJIT. It has been accepted for inclusion in Dissertations by an authorized administrator of Digital 
Commons @ NJIT. For more information, please contact digitalcommons@njit.edu. 
 
Copyright Warning & Restrictions 
 
 
The copyright law of the United States (Title 17, United 
States Code) governs the making of photocopies or other 
reproductions of copyrighted material. 
 
Under certain conditions specified in the law, libraries and 
archives are authorized to furnish a photocopy or other 
reproduction. One of these specified conditions is that the 
photocopy or reproduction is not to be “used for any 
purpose other than private study, scholarship, or research.” 
If a, user makes a request for, or later uses, a photocopy or 
reproduction for purposes in excess of “fair use” that user 
may be liable for copyright infringement, 
 
This institution reserves the right to refuse to accept a 
copying order if, in its judgment, fulfillment of the order 
would involve violation of copyright law. 
 
Please Note:  The author retains the copyright while the 
New Jersey Institute of Technology reserves the right to 
distribute this thesis or dissertation 
 
 
Printing note: If you do not wish to print this page, then select  















The Van Houten library has removed some of the 
personal information and all signatures from the 
approval page and biographical sketches of theses 
and dissertations in order to protect the identity of 






NEW SCREENING METHODOLOGY FOR SELECTION OF POLYMERIC 
MATERIALS FOR TRANSDERMAL DRUG DELIVERY DEVICES 
 
by 
Roberto P. Falcone 
 
As medical advances extend the human lifespan, the level of chronic illnesses will increase 
and thus straining the needs of the health care system that, as a result, governments will need 
to balance expenses without upsetting national budgets.        
           Therefore, the selection of a precise and affordable drug delivery technology is seen as 
the most practical solution for governments, health care professionals, and consumers.  
 Transdermal drug delivery patches (TDDP) are one of the best economical 
technologies that are favored by pharmaceutical companies and physicians alike because it 
offers fewer complications when compared to other delivery technologies. TDDP provides 
increased efficiency, safety and convenience for the patient. The TDDP segment within the 
US and Global drug delivery markets were valued at $5.6 and $12.7 billion respectively in 
2009. TDDP is forecasted to reach $31.5 billion in 2015.  
The present TDDP technology involves the fabrication of a patch that consists of a 
drug embedded in a polymeric matrix. The diffusion coefficient is determined from the slope 
of the cumulative drug release versus time. It is a trial and error method that is time and labor 
consuming. With all the advantages that TDDPs can offer, the methodology used to achieve 
the so-called optimum design has resulted in several incidents where the safety and design 
have been put to question in recent times (e.g. Fentanyl).  
            A more logical screening methodology is needed. This work shows the use of a 
modified Duda Zielinsky equation (DZE). Experimental release curves from commercial 
 
 
are evaluated. The experimental and theoretical Diffusion Coefficient values are found to be 
within the limits specified in the patent literature. One interesting finding is that the accuracy of 
the DZE is closer to experimental values when the type of Molecular Shape and Radius are 
used.  
            This work shows that the modified DZE could be used as an excellent screening tool to 
determine the optimal polymeric matrices that will yield the desired Diffusion Coefficient and 
thus effectively decreasing the amount of time and labor when developing TDDPs.
 
 
NEW SCREENING METHODOLOGY FOR SELECTION OF POLYMERIC 

































A Dissertation  
Submitted to the Faculty of 
New Jersey Institute of Technology 
In Partial Fulfillment of the Requirements for the Degree of 
Doctor of Philosophy in Material Science and Engineering 
 


























Copyright © 2015 by Roberto P. Falcone 
 




NEW SCREENING METHODOLOGY FOR SELECTION OF POLYMERIC 
MATERIALS FOR TRANSDERMAL DRUG DELIVERY DEVICES 
 






Dr. N.M. Ravindra, Co-Dissertation Advisor      Date 





Dr. Michael Jaffe, Co- Dissertation Advisor      Date 





Dr. Bozena Michniak Kohn, Committee Member     Date 
Professor, Department of Pharmaceutics, EM School of Pharmacy, Rutgers – The State 





Dr. Treena Arinzeh, Committee Member      Date 





Dr. Kamalesh K. Sirkar, Committee Member     Date 






Dr. Laurent Simon, Committee Member      Date 
Assistant Professor, Chemical Biological and Pharmaceutical Engineering, NJIT  
iv
BIOGRAPHICAL SKETCH
Author: Roberto P. Falcone
Degree: Doctor of Philosophy
Date: May 2015
Undergraduate and Graduate Education:
 Doctor of Philosophy in Materials Science and Engineering,
New Jersey Institute of Technology, Newark, NJ, 2015
 Master of Science in Chemical Engineering,
Manhattan College, Riverdale, NY, 1981
 Bachelor of Science in Physical Chemistry,
Fairleigh Dickinson University, Teaneck, NJ, 1979
Major: Material Science and Engineering
Presentations and Publications:
Falcone, R., Jaffe, M. and Ravindra, N.M., New screening methodology for
selection of polymeric matrices for transdermal drug delivery devices,






















This Dissertation is dedicated to the two people who have been quite influential and 
supportive even if one of them is no longer physically around but always in mind, my 







Over the past eight years, I have received support and encouragement from a great number of 
individuals. My doctoral co-advisors, Drs. N.M. Ravindra and M. Jaffe have been superb 
mentors, great colleagues, and unwavering friends. Their guidance has made this a thoughtful 
and highly rewarding journey. My thanks to Dr. Bozena Michniak Kohn not only for giving 
timely and insightful feedback but also providing several opportunities for presenting parts of 
this work. 
               I would like to thank the remaining dissertation committee members, Drs. Treena 
Arinzeh, Kamelesh Sirkar and Laurent Simon for their support and patience over the past four 
years as I moved from an idea to a complete study. In addition, I want to express my gratitude 
to Dr. David T. Stanton for providing the molecular shape simulation values without which 
this work would not have been completed.  
               Finally, thanks to my wife Pamela for spending time in proofreading and helping 
editing this dissertation throughout  the writing and along with mother in believing (and the 





TABLE OF CONTENTS 
Chapter              Page 
 
1    INTRODUCTION ...................................................................................................      1 
 
1.1  Objective ..........................................................................................................      1 
 
1.2  Transdermal Drug Delivery..............................................................................      1   
 
1.3  Scope of the Study ...........................................................................................    11 
 
1.4  Specific Objectives of the Study ......................................................................    12 
 
1.5  Thesis Organization .........................................................................................    13 
 
2   BACKGROUND ....................................................................................................     14 
 
2.1 ADME Mechanism ...........................................................................................    14 
 
2.2  First Pass Effect ..............................................................................................     15 
 
2.3  Routes of Administration.................................................................................     18 
 
   2.4  Therapeutic Index ...........................................................................................     19 
 
2.5  Structure of the Skin .......................................................................................     31 
 
2.5.1  Hypodermis ............................................................................................    37 
 
2.5.2  Adipose Tissue .......................................................................................    38 
 
2.5.3  Areolar Tissue ........................................................................................    39 
 
2.5.4  Dermis ....................................................................................................    40 
 
2.6  Epidermis ….….................................................................................................    45 
 
2.6.1 Stratum Corneum. ...................................................................................    47  
 
   2.6.2 Stratum Lucidum....................................................................................     47 
 
  2.6.3 Stratum Granosolum...............................................................................     47 
 





TABLE OF CONTENTS 
(Continued) 
 
Chapter    Page 
 
2.6.6  Merkel Cells.…......................................................................................     49 
 
2.6.7  Langerhans Cells..................................................................................       50 
 
2.6.8   Keratinocytes…....................................................................................      50 
 
2.6.9  Melanocytes..........................................................................................      51 
 
2.6.10 Macrophages........................................................................................      52 
 
2.7 Routes of Drug Entry into the Skin..................................................................      53 
 
2.8 TDD Techniques .............................................................................................      55 
 
2.9 Transdermal Patch Design ..............................................................................      57 
 
3   DIFFUSION CONCEPT .......................................................................................      61 
 
3.1 Definition..........................................................................................................      61 
 
3.2 Definition of Molecular Models .......................................................................     62 
 
3.3 Free Volume......................................................................................................     68 
 
3.4 Free Volume Models.........................................................................................     72 
 
3.5 Effect of Various Conditions. ...........................................................................     77 
 
3.5.1 Effect of Molecular Radius......................................................................     77 
 
3.5.2 Effect of Molecular Shape........................................................................    81 
 
3.6 Theoretical Background.....................................................................................    82 
 
4   EXPERIMENTALRESULTS .................................................................................    84 
 
4.1 Experimental Method ........................................................................................    84 
 





TABLE OF CONTENTS 
(Continued) 
 
Chapter             Page 
 
4.3 Nicotine Values Estimation .….........................................................................    90 
 
4.4 Estimation of the Values of Polymeric Matrix Components. ….........................  94 
 
4.5 Energy Calculations. ........................................................................................     95 
 
4.6 Effect of Molecular Radius of Gyration ..........................................................     98 
 
4.7 Effect of Molecular Shape. ..............................................................................   100 
 
4.8 Effect of Combining Molecular Radius of Gyration and Shape factors. ..........  102  
 
5   DISCUSSION.........................................................................................................   107  
 
6   CONCLUSIONS....................................................................................................    112 
 
7   FUTURE WORK ...................................................................................................   115 
 
APPENDIX A  ............................................................................................................   116 
 
APPENDIX B  ............................................................................................................   120 
 
APPENDIX C  ............................................................................................................   122 
 
APPENDIX D  ............................................................................................................   125 
 
 APPENDIX E  ............................................................................................................    137 
 
















LIST OF FIGURES 
 
Figure Page 
1.1  TDD Global Sales (2007 – 2014)…....………………..…………………………. 4 
1.2  Manufacturer’s Revenue from TDD Technologies (2010 – 2017)) …………..…     5 
1.3  Timeline showing transdermal patches date of approval by the FDA …….……. 6 
1.4  Global Percent sales for Different TDD ………………………………………… 8 
1.5 Cumulative number of transdermal drugs approved by the FDA………………...  9 
1.6 In vitro release of Nitrendipine from transdermal patches…………………….… 10 
2.1 First pass effect ……………………………………………………………....….. 15 
2.2 Different routes for therapeutic actives to enter the body …...…………………...      17 
2.3 Typical plot of Cp versus time after oral administration fast and slow ...………..       17 
2.4 Typical plot of Cp versus time after sublingual administration ….………………       18 
2.5 Typical plot of Cp versus time after buccal administration………………………       18 
2.6 Typical plot of Cp versus time after rectal administration……………………….       19 
2.7 Typical plot of Cp versus time during an IV infusion administration………….       25 
2.8 Typical plot of Cp versus time after intramuscular administration.……………...       26 
2.9 Typical plot of Cp versus time after subcutaneous administration ...............…….             27 
2.10 Various routes of drug administration through injections.........……………….… 
 
      28 
2.11 Plot of drug blood concentration versus time of different parenteral systems........      29 
2.12 Typical plot of Cp versus time after inhalation administration............………......       30 
2.13 Plot of drug plasma concentration versus time topical administration…………...    
    
      31 








Figure    Page 
2.15 Skin structure ………………………………………………………………….....       36 
2.16 Hypodermis structure ……..……………………………...………………………      37 
2.17 Adipose tissue/cells ………………………………………………………………      38 
2.18 Areolar tissue ……………………………………………………………….........       39 
2.19 Dermis …………….……….………..……………………………………………      40 
2.20 Papillary and Reticular layers ………………………………………...….………       42 
2.21 Fibroblasts ………………………………………………………………………..      43   
2.22 Tropocollagen structure ………………………………………………………….       44 
2.24 Layers of the epidermis………………………… ……….…………….…………      45 
2.25 Schematic image showing a section of epidermis with epidermal layers labeled...       46 
2.26 Types of cells present in the epidermis layers …….……………………………..       48 
2.27 Merkel cells ………………………………………………………………………      50  
2.28 Langerhans cells ………………………………………………………………….      51    
2.29 Keratinocytes as seen under a microscope ……………………………………….      52 
2.30 Melanocytes ……………………………………………………………………...       52  
2.31 Macrophages ……………………………………………………………………..       53 
2.32 Delivery Skin Routes …………………………………………………………….       54 
2.33 Brick and Mortar ………………………………………………………………....      55 
2.34 Hypothetical blood level pattern ……………………………………..……….….       57  








Figure    Page 
2.36 TDDP release mechanism ………………………………………………………..      59 
3.1 Fick’s self-diffusion ……………………………………………………………...        61 
3.2 Molecular mobility through voids / oscillating cavities …………………………       63 
3.3 Diffusion motion …………………………………………………………………        63 
3.4 Mechanism steps and activation energies ………………………………………..        65 
3.5 Free Volume Model ……………………………………………………………...       68 
3.6 Eyring Molecular Model …………………………………………………………       69 
3.7 Free volume 3D representation …………………………………………………..       70 
3.8 Representation of volume disposition in a rubbery matrix as function of T …….       71 
3.9 Cohen and Turnbull graphical representation ……………………………………      74 
3.10 Comparison between radiuses of rotation, hydrodynamic, gyration and mass .….      79 
3.11 3D nicotine model ………………………………………………………………..                      81 
4.1 Nicotine ultraviolet absorption chart …………………………………………….       85 
4.2 Diagram of a typical commercial nicotine patch.………………………………...         87 
4.3 Franz static cell components …………………………………………………......        88 
4.4 Fully assembled typical Franz static cell ………………………………………...       89 
4.5 Cumulative nicotine release ……………………………………………………...       90 
4.6 Nicotine molecular structure ……………………………………………………..      92 
4.7 Cumulative release comparison between Deep and Decal………………………….       99 








Figure    Page 
4.9 Diffusion coefficient comparison between ξ, ξL and experimental values ……...     102 
4.10 Fully Comparison between DζL and DRh………………………………………….     103  
4.11 Diffusion coefficient comparison between experimental and DRg (0.77) +ξ+ξl(IIa) …..    104 
4.12 Comparison of Diffusion coefficient of experimental and D Rg(1.732)+ξ+ξl(IIb ……..     105 
4.13 Comparison of Diffusion coefficient of experimental and DRg (0.77) +ξL+ξ (IIIa) ……    106 
4.14 Comparison of Diffusion coefficient of experimental and D Rg(1.732)+ξL+ξ(IIIb) …....    107 
5.1 Comparison of Diffusion Coefficient using shape factors……………………….    108 
5.2 Comparison of Diffusion Coefficients …………………………………………...     109 
5.3 Comparison of Diffusion Coefficient using different molecular shape and radius     110 
5.4 Overall Comparison of Diffusion Coefficients …………………………………..     111 
6.1 De Gennes Molecular Representation……………………………………………    114 
   
6.2 De Gennes Molecular Reptation Pattern …………………………………………    115 






















LIST OF SYMBOLS 
 
Mt Amount of drug available at time t 
Min Initial amount of drug introduced into the body 
Ct Initial drug concentration 
C∞ Drug concentration at time t 
Vp Plasma volume 
TI Therapeutic Index 
D Diffusion Coefficient 
Vf Free Volume 
Tg Glass Transition Temperature 
V1
* 
  Critical molar free volume needed for any 
displaced singularity of species 1 to move  
 
VFH Free volume per mole of all individual 
moving solute units in the matrix 
 
D01      Temperature – independent constant 
 







The objective of this dissertation is to present a screening methodology for trans-dermal 
patches (TDDP) that will simplify and expedite the design implementation of new passive 
drug delivery systems. These patches can be used to increase the number of therapeutic 
devices in the market, thus, helping to improve the quality of life. 
The screening methodology uses physical parameters that comprise free volume, 
thermodynamic estimators and material—solute (active) interactions.  This methodology has 
been compared with commercially available TDDP to determine the validity of such an 
approach. 
1.2 Transdermal Drug Delivery 
As medical technology continues to improve human lifespan, it will increase the number of 
chronic illnesses and consequently strain the needs of the health care system. Having 74% of 
65- to 69-year-olds in the US, stricken with one or more chronic conditions, creates an 
increasing burden on health care providers, patients, and their caregivers. This situation will 
place a greater emphasis on the selection of a more precise drug delivery technology for the 
patient and the caregiver. (1) 
Statistics: 
1. It is projected that US health care spending will reach $4.3 trillion in 2018. 




3. It is estimated that 25% of elderly people will take a minimum of three    
            medications. 
4.        The daily average number of pills ingested per patient in a nursing home is 13. 
5.        The number of elderly people who have swallowing difficulties (dysphagia) is   
           65%. 
 
6.       Twenty-three percent of caregivers indicate challenges with managing  
           medications. 
 
7.        Forty percent of elderly people must be admitted into nursing homes because of    
           their inability for self-medication. 
 
In this context, transdermal drug delivery patches (TDDP) are considered to be the 
best alternative drug delivery technology that is highly sought by pharmaceutical companies 
and physicians alike(2). TDDP offer fewer complications when compared to other delivery 
technologies. Additional benefits include increased efficiency, safety, and convenience for 
the patient. (3, 4)  
            The TDD market within the US, in 2009, was valued at $5.6 billion,(4) The size of the 
global market was estimated by Jain Pharma Biotech to be $12.7 billion in 2005 with 
expected increases to $21.5 billion and $31.5 billion in 2010 and 2015 respectively (5).  
            However, on a global perspective, drug delivery systems have shown a dramatic sales 
growth from $42B in 2007 to $80B in 2014 as shown in Figure 1.1. Moreover, TDDs 
contributed 75 % of these sales in 2007 ($30B).  Although their contribution in 2014 is 
estimated to be 57 % ($45B) and smaller when compared with 2007 figures. This category 








Figure 1.1 TDD Global Sales (2007-2014) 
Source: Advanced Drug Delivery Systems: New Developments, New Technologies, 
(http://www.bccresearch.com/market-research/pharmaceuticals/drug-delivery-systems-phm006g.html), 
Accessed on October 28, 2014  
Another advantage that TDD devices offer is the revenues that drug manufacturers 
get from leveraging this technology. It is expected that revenues will grow from $628.6M in 
2010 to an estimated $902.1M in 2017. This represents an approximate 50% growth as seen 






Figure 1.2  Manufacturer’s Revenue from TDD Technologies (2010-2017) 
 
Source: Wright, P., Transdermal drug delivery looks for new frontiers,    
(http://pharmaceuticalcommerce.com/manufacturing_and_packaging?articleid=2677).    
Accessed on October 28, 2014.  
 
Because of the advantages offered by TDDs, research and patents using them have 
substantially increased since the FDA approved the first TDD patch in 1981. The active drug 
was scopolamine used for the treatment of motion sickness. Figure 1.3 shows the timeline of 






Figure 1.3 Timeline showing transdermal patches since their date of approval by FDA 
Source: Zielinski, B., Controlled Drug Delivery, Transdermal Drug Delivery System (TDDS),  
Brown University Lecture, https://canvas.brown.edu/courses/773684/.../download   
Accessed on November 29, 2014. 
 
Table 1.1 provides a summary of the most popular TDDs approved by the FDA along 














Table 1. 1 Commercially Available Drugs in the Form of Transdermal Patches 
Approval 
Year 
Drug/Product Name Purpose Marketing Company 
1979 Scopolamine/Transderm-Scop Motion sickness Novartis Consumer 
Health (Parsippany, NJ, 
USA) 
 
1981 Nitroglycerin/Transderm-Nitro Angina pectoris Novartis 
 
1984 Clonidine/Catapres-TTS Hypertension Boehringer Ingelheim 
(Ridgefield, CT, USA) 
 
1986 Estradiol/Estraderm Menopausal symptoms 
 
Novartis 
1990 Fentanyl/Duragesic Chronic pain Janssen Pharmaceutica 
(Titusville, NJ, USA) 
 
1991 Nicotine/Nicoderm, Habitrol, 
ProStep 
Smoking cessation GlaxoSmithKline 
(Philadelphia), Novartis, 
Elan (Gainesville, GA, 
USA) 
 
1993 Testosterone/Testoderm Testosterone deficiency Alza (Mountain View, 
CA, USA) 
1995 Lidocaine with epinephrine 
(iontophoresis)/Iontocaine 
Local dermal analgesia Iomed (Salt Lake City, 
UT, USA) 
 





1999 Lidocaine/Lidoderm Post-herpetic neuralgia 
pain 
Endo Pharmaceuticals 
(Chadds Ford, PA, USA) 






2003 Estradiol with 
levonorgestrel/Climara Pro 
Menopausal symptoms Bayer Healthcare 
Pharmaceuticals (Wayne, 
NJ, USA) 
2003 Oxybutynin/Oxytrol Overactive bladder Watson Pharma (Corona, 
CA, USA) 
 
2004 Lidocaine (ultrasound)/SonoPrep Local dermal anesthesia Echo Therapeutics 
(Franklin, MA, USA) 
 
2005 Lidocaine with tetracaine/Synera Local dermal analgesia Endo Pharmaceuticals 
 
2006 Fentanyl HCl 
(iontophoresis)/Ionsys 
Acute postoperative pain 
 
Alza 
2006 Methylphenidate/Daytrana Attention deficit 
hyperactivity disorder 
Shire (Wayne, PA, USA) 
 
2006 Selegiline/Emsam Major depressive 
disorder 
Bristol-Myers Squibb 





Table 1.2 Commercially Available Drugs in the Form of Transdermal Patches 
(Continued) 
 
2007 Rotigotine/Neupro Parkinson’s disease 
Schwarz 
Pharma (Mequon, WI, 
USA) 
 
2007 Rivastigmine/Exelon Dementia Novartis 
 
Source: VIJAY KRISHNA RACHAKONDA, EFFECTIVE SCREENING OF CHEMICAL PENETRATION 
ENHANCERS FOR TRANSDERMAL DRUG DELIVERY 
https://shareok.org/bitstream/handle/11244/9658/Rachakonda_okstate_0664M_2865.pdf?sequence=1, 
Accessed on May 10, 2015 
 
Figure 1.4 shows the percent of global sales for different transdermal patch use segments.            
       
 
 
Figure 1.4 Global Percent sales for Different TDD Segments 
Source: Rachakonda, V.K., Effective Screening of Chemical Penetration Enhancers for Drug Delivery, Master 
Thesis, Oklahoma State University, p. 2, 2006. 
 
          The cumulative number of TDDs approved by the FDA is shown in Figure 1.5.  This 




There are currently 19 drugs and drug combinations administered by various delivery 
methods that are approved in the United States as shown in Figure 1.5(6). 
 
Figure 1.5 Cumulative number of transdermal drugs approved by the FDA  
 
Source: Prausnitz, M.R., Mitragotri, S. and Langer, R., Current status and future potential of transdermal drug 
delivery, Nature Reviews Drug Discovery, 3, 115-124, 2004 
 
           There are several TDDs in the market today (4) and the development trend continues as 
described in appendices A, B, and C. 
           The present TDDP methodology involves the fabrication and testing of the in-vitro 
release of drug embedded within a polymeric matrix in which the cumulative drug release is 
plotted against time as shown in Figure 1.6(5). This permits an estimation of the Diffusion 
Coefficient for the system in question which in turn is used to calculate the optimal usage to 
be expected when used by the patient as well as establishing safety factors for maximum 





Figure 1.6 In vitro release of Nitrendipine from transdermal patches 
Source: Gannu, R., Vishnu, Y. V. Kishan, V., and Rao, M., Development of nitrendipine  
transdermal patches: In vitro and ex vivo characterization, Current Drug Delivery, 4, 69- 
76, 2007. 
 
This is obtained via a trial and error method, which is time and labor consuming. 
Although, with all the advantages that TDDs can offer, the methodology that is used to 
achieve the so-called optimum design has created several incidents in which the safety and 





Table 1.3 Transdermal fentanyl patch medication incidents classified by medication system 
stage involved 
Stage involved All incidents 
(n=3271) 
Incidents resulting in 
harm or death (n=271) 
Number  Percent* Number  Percent ** 
Physician ordering (prescribing) 419 12.8% 38 14.0% 
Order entry and transcription 417 12.8% 16 5.9% 
Preparation, dispensing and delivery of 
drugs 
397 12.1% 17 6.3% 
 










Monitoring/follow-up of drug use 185 5.7% 22 8.1% 
N/A 168 5.1% 1 0.4% 
Other 41 1.3% 6 2.2% 
Total selections: 3319 101.5% 280 103.3% 
Total incidents: 3271 100.00% 271 100.00% 
 
* Percentage is calculated based on the total number of medication incidents (n = 3271). 
Since a medication incident may involve more than one stage selection, the total percentage 
is greater than 100%. 
** Percentage is calculated based on the total number of medication incidents with outcome 
of harm or death (n = 271). Since a medication incident may involve more than one stage 
selection, the total percentage is greater than 100%. 
 
Source:  Cheng, R., Samples, C., Ho, C., Lee, C., Cohen, M., U. D., Cousins, D., and Kirke, C., Medication 
incidents related to the use of fentanyl transdermal systems: An international aggregate analysis, International 
Medication Safety Network (IMSN), 2008 http://www.intmedsafe.net/wp-






This has prompted the redesign of several TDDPs since the approval of the first patch in 
1981(10). There are 675 patents and patent applications, relating to this technology in the US 
alone (6, 7). The majority of these submissions have taken place since the late 1990s.          
          Therefore, alternate drug delivery technologies are highly sought by pharmaceutical 
companies and physicians alike, thus, increasing efficiency, safety, and convenience for the 
patient.  
1.3 Scope of the Study 
The purpose of this work is to show a new approach for setting a more robust screening 
method when considering redesigning or designing new TDD patches, especially for the ones 
where the drug is embedded within the body of the matrix. 
             The diffusion coefficient is determined by measuring the cumulative release against 
time. These experiments are usually done using in-vitro techniques where the cumulative 
amount is quantified by analytical techniques such as high performance liquid 
chromatography (HPLC), infrared spectroscopy (IR), and ultraviolet spectroscopy (UV) 
among others.  Along with the selection and fabrication techniques described in section 1.2, 
this can be resource (i.e., labor and equipment) and time consuming, cost prohibitive, and 
have limited throughput. Moreover, these protocols provide an indirect assessment on how 
effective the TDD will be when applied unto the skin.  
              Models to predict the diffusion coefficient have been used to measure the 
permeation of solutes through polymeric membranes. This suggests that these models can be 
used to predict the diffusion coefficient of drug actives through the polymeric films that are 




diffusion of drug actives. No research to date has demonstrated how the model compares 
with the experimental techniques that are presently in use. 
1.4 Specific Objectives of the Study 
Objective 1: Comparison between experimentally obtained and calculated diffusion  
                      coefficients. 
 
In this study, the diffusion coefficient of nicotine was experimentally obtained and compared 
with the calculated value using the Dudas Zielinski equation (DZE).   
           This is because most of the physical parameters of nicotine were not readily available 
in the open literature that is required by the DZE, to calculate the diffusion coefficient, they 
had to be estimated from group contribution methods. The results show a good agreement 
between the experimental and calculated values, thus, confirming the usefulness of DZE for 
predicting meaningful diffusion coefficient values. 
 
Objective 2: Comparison between radius of gyration (Rg) and hydrodynamic radius (Rh). 
 
The solute/diffusant is always assumed to have a spherical shape (Rh). However, since most 
molecules could be rotating around their center axis (Rg) while diffusing through the 
polymeric membrane, calculated Rg values of nicotine were estimated and incorporated into 








Objective 3: The effects of molecular shape on the diffusion coefficient. 
 
Another parameter included in the DZE is the molecular shape. The molecular shape of 
nicotine was calculated using the Vrentas (ξL) and Nobrega (ξ) approximations that were 
incorporated into the DZE. 
 
1.5 Thesis Organization 
The thesis consists of six chapters. Chapters one and two introduce the topic and provide a 
literature review and background for this work. Chapter 3 shows the theoretical foundations 
while chapter 4 describes the experimental and theoretical determination of the diffusion 
coefficient. The Discussion and Conclusions details the results from this work along with 









2.1 ADME Mechanism 
For any treatment to be effective, the active ingredients must undergo the physiological 
process known as Absorption Distribution Metabolism Excretion (ADME) (11).      
           These are the steps that any ingredient that the body is exposed to must undergo in 
order to be assimilated. Vergnaud and Rosca defined ADME as follows, “Absorption is the 
drug assimilation from the gastrointestinal tract (GIT) into the bloodstream or the lymphatic 
system. These molecules must go through several complex membranes made of lipid 
barriers, thus, involving different steps.”(12) 
 The steps are as follows: 
1. Drug dissolution into the membrane, 
2. Transcellular passive diffusion or active transport through the membrane walls, and 
3. Luminal and epithelial metabolism. 
            This can be considered as a first order kinetics. The drug concentration in the GIT 
will decrease as shown in equation (2.1): 
Mt = Min exp (-kat) (2.1) 
where,  
ka is the rate absorption constant, 
Min is the initial amount of drug introduced into the body, 
Mt is the amount of drug available at time t, 




This will lead to a concurrent drug concentration increase in the blood: 
Ct = C∞ [1-exp (-kat)] (2.2) 
where,  
Ct is the initial drug concentration, 
C∞ is the drug concentration at time t, 
The unbound/free drug concentration in the plasma is: 
C∞ = Min / Vp (2.3) 
and Vp is the plasma volume.  
          Then ka is estimated from the drug profile in the bloodstream at time t.  The change in 
maximum drug concentration with time is described in equation (2.4): 
Tmax = 1 / (ka – ke) ln (ka/ ke) (2.4) 
           Distribution is the step where the unbound drug molecule, present in the bloodstream, 
passes into the tissues and organs. The human organism consists of cells and fluids. The fluid 
can be divided into three distinctive compartments: intravascular, interstitial or extracellular, 
and intracellular. 
           Metabolism can be defined as the sum of all the chemical reactions involved in the 
biotransformation of endogenous and exogenous substances that can occur in the cells. 
Although several processes are part of the biotransformation processes, catabolic and 
anabolic are the most predominant. Catabolic is the breakdown of the drug into simpler 






2.2   First Pass Effect 
The first pass effect is defined for the hepatic metabolism of a drug when it is absorbed from 
the gastrointestinal tract and delivered to the liver via the bloodstream as seen in Figure 2.1. 
The greater the first pass effect, the lesser will be the amount of drug to reach the systemic 
circulation. This is the case for orally delivered drugs. 
 
 
Figure 2.1 First pass effect 
Source: Boomer, D., PHAR 7633 Chapter 7, Routes of Drug Administration  
http://www.boomer.org/c/p4/c07/c07.pdf 
 
The effect of the first pass effect or extraction ratio (ER) is given by equation (2.5): 
ER = CL liver / Q (2.5) 






Systemic drug bioavailability (F) may be determined from the extent of absorption (f) and 
the extraction ratio (ER) as described in equation (2.6): 
F = f x (1 -ER)  (2.6) 
           The greater the first pass effect, the lower is the rate and extent of the drug reaching 
cells and target organs. This is also known as drug bioavailability. 
Excretion or clearance of the active drug usually takes place in the kidney and intestinal tract 
with the exception of gaseous deliveries such as anesthetics and inhalers, which are secreted 
through the lungs. The main excretion route is via the kidneys where the rate and extent is 
regulated by glomerular filtration, tubular reabsorption, and secretion. Clearance (Cl) 
happens by blood perfusion through the extraction organs. Extraction (E) is directly related 
to the drug that is excreted or metabolized. The following relationship is found: 
Cal = QE (2.7) 
where, Q is the blood flow through the organ where secretion is taking place. Since the 
secretion organs are mostly the liver and kidneys, with hepatic clearance Clh and renal 
clearance Clr, the overall mass systemic balance Cl is: 
Cl = Clh + Clr (2.8) 
            Thus, clearance is a function of the necessary blood volume passing through the 
excretion organ to discharge the drug in a certain period of time: 
RE = Cl*C (2.9) 






2.3 Therapeutic Index (TI) 
 
Ehrlich defined the Therapeutic Index (TI) as the relationship between the minimum curative 
and maximum tolerated dose. In pharmacological terms, TI is the ratio associating the 
median lethal dose (drug concentration in the bloodstream that promotes the deaths of 50% 
of the test population, LD50) to the median effective dose (drug concentration in the 
bloodstream that is effective for 50% of the test population, ED50): 
TI = (LD50) / (ED50) (2.10) 
            TI is a derivation of the threshold model that assumes an exposure concentration, or 
threshold, for the drug to be effective. 
 
2.4 Routes of Administration 
There are several approaches or routes that drugs can be delivered as shown in Figure 2.2. 
 
Figure 2.2 Different routes for therapeutic actives to enter the body 
Source: Administration, Merck Manual, 
http://www.merckmanuals.com/home/drugs/administration_and_kinetics_of_drugs/drug_administration. html. 
Accessed on November 28, 2014 
 
           For the subcutaneous route, a needle is inserted into the fatty tissue just beneath the 




carried away by the bloodstream. Alternatively, a drug reaches the bloodstream through the 
lymphatic vessels. Protein drugs that are large in size usually reach the bloodstream through 
the lymphatic vessels because these drugs move slowly from the tissues into capillaries. The 
subcutaneous route is used for many protein drugs because such drugs would be destroyed in 
the digestive tract if they were taken orally.  
        Certain drugs (such as progestins used for birth control) may be given by inserting 
plastic capsules under the skin (implantation). Although this route of administration is rarely 
used, its main advantage is to provide a long-term therapeutic effect (for example, 
etonogestrel that is implanted for contraception may last up to 3 years).  
          The intramuscular route is preferred to the subcutaneous route when larger volumes 
of a drug product are needed. Because the muscles lie below the skin and fatty tissues, a 
longer needle is used. Drugs are usually injected into the muscle of the upper arm, thigh, or 
buttock. The rate of absorption of the drug into the bloodstream depends, in part, on the 
blood supply to the muscle. The sparser the blood supply, the longer it takes for the drug to 
be absorbed.  
           For the intravenous route, a needle is inserted directly into a vein. A solution 
containing the drug may be given in a single dose or by continuous infusion. For infusion, 
the solution is moved by gravity (from a collapsible plastic bag) or, more commonly, by an 
infusion pump through a thin flexible tubing to a tube (catheter) inserted in a vein, usually in 
the forearm. Intravenous administration is the best way to deliver a precise dose quickly and 
in a well-controlled manner throughout the body. It is also used for irritating solutions, which 




           When given intravenously, a drug is delivered immediately to the bloodstream and 
tends to take effect more quickly than when given by any other route. Consequently, 
healthcare practitioners closely monitor people who receive an intravenous injection for 
signs that the drug is working or is causing undesired side effects.     
            Also, the effect of a drug given by this route tends to last for a shorter time. 
Therefore, some drugs must be given by continuous infusion to keep their effect constant.    
            These routes can be divided into two potential avenues of entry into the human body.  
They are categorized as: 
 Enteral,  
 Parenteral,  
 inhalation, and 
 Topical and local application. 
Enteral is when the drug is placed directly in the GIT.  The enteral path could be subdivided 
as: 
Oral – this is when the drug is swallowed. The efficacy and delivery can vary depending on 
the rate of how the active can dissolve and be quickly absorbed by the lower intestine as seen 







Figure 2.3 Typical plot of Cp versus time after oral administration fast and slow 
 
Source: Boomer, D., PHAR 7633 Chapter 7, Routes of Drug Administration 
http://www.boomer.org/c/p4/c07/c07.pdf. Accessed on November 28, 2014 
 
         Sublingual is when the drug is placed under the tongue. The drug release is fast and 









        
 
Figure 2.4 Typical plot of Cp versus time after sublingual administration 
Source: Boomer, D., PHAR 7633 Chapter 7, Routes of Drug Administration  
http://www.boomer.org/c/p4/c07/c07.pdf Accessed on November 28, 2014 
 
         Buccal is when the active drug is placed in the buccal cavity where it dissolves / is 
transported through the mucous membrane. The drug release is slow and more consistent 










        
Figure 2.5 Typical plot of Cp versus time after buccal administration 
Source: Boomer, D., PHAR 7633 Chapter 7, Routes of Drug Administration  
http://www.boomer.org/c/p4/c07/c07.pdf. Accessed on November 28, 2014 
 
         Rectal is when the drug is directly absorbed through the rectum. It shows a drug release 
pattern similar to sublingual delivery systems. This is because both technologies must go 













Figure 2.6 Typical plot of Cp versus time after rectal administration 
Source: Boomer, D., PHAR 7633 Chapter 7, Routes of Drug Administration  
http://www.boomer.org/c/p4/c07/c07.pdf. Accessed on November 28, 2014 
 
   Parenteral is when the drug is not placed directly in the GIT. The parenteral path   
could be subdivided as: 
          Intravenous (IV, IA)—placing a drug directly into the bloodstream. The absorption 
phase is bypassed (100% bioavailability). It is precise, accurate and almost immediate onset 









Figure 2.7 Typical plot of Cp versus time during an IV infusion administration 
Source: Boomer, D., PHAR 7633 Chapter 7, Routes of Drug Administration  
http://www.boomer.org/c/p4/c07/c07.pdf. Accessed on November 28, 2014 
 
          Intramuscular is similar to Intravenous in which a very rapid absorption of drugs in 












Figure 2.8 Typical plot of Cp versus time after intramuscular administration 
Source: Boomer, D., PHAR 7633 Chapter 7, Routes of Drug Administration  
http://www.boomer.org/c/p4/c07/c07.pdf 
 





Figure 2.9 Typical plot of Cp versus time after subcutaneous administration  
 
Source: Boomer, D., PHAR 7633 Chapter 7, Routes of Drug Administration  
http://www.boomer.org/c/p4/c07/c07.pdf 
 
           Figures 2.8 and 2.9 show plot of Cp versus time after intramuscular administration 










       
Figure 2.10 Various routes of drug administration through injections 
Source: Rachakonda, V.K., Effective Screening of Chemical Penetration Enhancers for Drug    
Delivery, Master Thesis, Oklahoma State University, p. 17, 2006. 
 
         Figure 2.10 shows the various routes for drug administration.  These include: 
 intra-arterial 
 intra-articular, and 
 Intra-dermal. 
Inhalation is when the active drug is delivered directly from the lungs. Topical and local 
application is when the drug is delivered upon and through the skin. Parenteral is an 
intramuscular (IM) drug injected into skeletal muscle. Figures 2.11 – 2.14 show various case 






Figure 2.11 Plot of drug blood concentration versus time comparison of different    
parenteral delivery systems 
 
Source: Pharmacokinetics Presentation, 
http://web.calstatela.edu/faculty/mchen/454L%lectures/pharmacokinetics.ppt 
Accessed on November 29, 2014 
 
             Inhalation is absorption through the lungs by means of gaseous, volatile agents 
and aerosols. This creates a rapid onset of action due to rapid access to circulation, 
because of the following factors 
a. large surface area, 
b. thin membranes separates alveoli from circulation, and 
c. high blood flow. 





Figure 2.12 Typical plot of Cp versus time after inhalation administration 
Source: Boomer, D., PHAR 7633 Chapter 7, Routes of Drug Administration                  
http://www.boomer.org/c/p4/c07/c07.pdf. Accessed on November 29, 2014 
 
         Topical administrations leverage the mucosal membranes (e.g., eye drops, antiseptic, 
sunscreen, and callous removal, nasal) and skin to deliver drug actives by means of  
      a. dermal - rubbing in of oil or ointment (local action) and 
b. transdermal - absorption of drug through skin (systemic action).  
providing a longer time which increases effectiveness. Topicals can be considered as 





Figure 2.13 Typical plot of Cp versus time after topical administration 
Source: Boomer, D., PHAR 7633 Chapter 7, Routes of Drug Administration      




Figure 2.14 Plot of drug plasma concentration versus time comparison between IV and                                                             
oral administration.  
 
Source:  Tangphao, O.,  Grossmann, M., Chalon, S., Hoffman, B.B., and Blaschke, T.F.,     
Pharmacokinetics of intravenous and oral l-arginine in normal volunteers,  




        Tables 2.1 and 2.2 summarize the routes of administration of drugs and their associated 
advantages and disadvantages, respectively. Table 2.1 shows the effective time by the 
different routes of administration. 
Table 2.1 Routes of Administrations and Effective Times 
Route of Administration Effective Time 
Intravenous 30-60 seconds 
Inhalation 2-3 minutes 
Sublingual 3-5 minutes 
Intramuscular 10-20 minutes 
Subcutaneous 15-30 minutes 
Rectal 5-30 minutes 
Ingestion 30-90 minutes 
 
Source: Manitoba Health, ROUTES for DRUG ADMINISTRATION, EMERGENCY TREATMENT   
GUIDELINES, APPENDIX A2, http://www.gov.mb.ca/health/ems/guidelines/docs/A2.08.03.pdf.   Accessed 
on November 30, 2014. 
         



















Oral Convenient - portable, safe, no 
pain, easy to take. 
Cheap - no need to sterilize (but 
must be hygienic of course), 
compact, multi-dose bottles, 
automated machines produce 
tablets in large quantities. 
Variety of dosage forms 
available - fast release tablets, 
capsules, enteric coated, layered 
tablets, slow release, 
suspensions, mixtures 
Sometimes inefficient - high dose or 
low solubility drugs may suffer poor 
availability, only part of the dose 
may be absorbed. 
First pass effect - drugs absorbed 
orally are transported to the general 
circulation via the liver. Thus drugs 
which are extensively metabolized 
will be metabolized in the liver 
during absorption. 
Food - Food and GI motility can 
affect drug absorption. Often, patient 
instructions include a direction to 
take with food or take on an empty 
stomach. Absorption is slower with 
food for tetracycline and penicillin, 
etc. 
Local effect - Antibiotics may kill 
normal gut flora and allow 
overgrowth of fungal varieties. 
Thus, antifungal agent may be 
included with an antibiotic. 
Unconscious patient - Patient must 
be able to swallow solid dosage 




First pass - The liver is by-
passed, thus, there is no loss of 
drug by first pass effect for 
buccal or sublingual 
administration 
 Bioavailability is higher. Rapid 
absorption - Because of the good 
blood supply to the area of 
absorption is usually quite rapid, 
especially for drugs with good 
lipid solubility. 
Drug stability - pH in mouth 
relatively neutral (cf. stomach - 
acidic). Thus, a drug may be 
more stable. 
Holding the dose in the mouth is 
inconvenient. If any part of the dose 
is swallowed, that portion must be 
treated as an oral dose and subject to 
first pass metabolism. 
Usually, more suitable for drugs 
with small doses. 







Table 2.3 Advantages and Disadvantages of different Types of Administration 
(Continued) 
Rectal By-pass liver - Some (but not all) of 
the veins draining the rectum lead 
directly to the general circulation, 
thus, bypassing the liver. Therefore, 
there may be a reduced first pass 
effect. 
Useful - This route may be most 
useful for patients unable to take 
drugs orally or with younger 
children. 
Erratic absorption - Drug absorption 
from a suppository is often 
incomplete and erratic. However, for 
some drugs it is quite useful. There is 
research being conducted to look at 
methods of improving the extent and 
variability of rectal administration.  
Absorption from solutions used as an 
enema may be more reliable. Not well 
accepted. May be some discomfort. 
Intravenous 
(IV) 
Rapid - A quick response is 
possible. Plasma concentration can 
be precisely controlled using IV 
infusion administration. 
Total dose - The whole dose is 
delivered to the bloodstream. That 
is the bioavailability is generally 
considered 100% after IV 
administration. Larger doses may 
be given by IV infusion over an 
extended time. 
 Poorly soluble drugs may be given 
in a larger volume over an extended 
time period. 
Veins relatively insensitive - to 
irritation by irritant drugs at higher 
concentration in dosage forms. 
Suitable vein - It may be difficult to 
find a suitable vein. There may be 
some tissue damage at the site of 
injection. 
May be toxic - Because of the rapid 
response, toxicity can be a problem 
with rapid drug administrations. For 
drugs where this is a particular 
problem the dose should be given as 
an infusion, monitoring for toxicity. 
Requires trained personnel - Trained 
personnel are required to give 
intravenous injections. 
Expensive - Sterility, pyrogen testing 
and larger volume of solvent means 
greater cost for preparation, transport, 
and storage. 
Subcutaneous Can be given by patient (e.g. in the 
case of insulin). 
Absorption can be fast from 
aqueous solution but slower with 
depot formulations.  
Absorption is usually complete. 
Improved by massage or heat.  
Vasoconstrictor may be added to 
reduce the absorption of a local 
anesthetic agent, thereby 
prolonging its effect at the site of 
interest. 
Can be painful. Finding suitable sites 
for repeat injection can be a problem. 
Irritant drugs can cause local tissue 
damage. 
Maximum of two ml injection, thus, 














Table 2.4 Advantages and Disadvantages of different Types of Administration 
(Continued) 
 
   
Intramuscular Larger volume than SC can be 
given by IM. They may be easier to 
administer than IV injections. 
A depot or sustained release effect 
is possible with IM injections (e.g. 
procaine penicillin). 
Absorption can be rapid from 
aqueous solution. 
 
Trained personnel required for 
injections. The site of injection will 
influence the absorption; generally, 
the deltoid muscle provides faster and 
more complete absorption. 
Absorption is sometimes erratic, 
especially for poorly soluble drugs 
(e.g. diazepam, phenytoin).  
The solvent may be absorbed faster  
 than the drug causing precipitation of     
 the drug at the site of injection. 
 Irritating drug may be painful. 
Inhalation May be used for a local effect, e.g. 
bronchodilators. 
Can be used for systemic effect 
(e.g. general anesthesia). 
Rapid absorption by-passing the 
liver. 
 Absorption of gases is relatively    
 efficient; however, solids and liquids  
 are excluded if larger than 20 micron  
 and even then only 10% of the dose       
 may be absorbed.  
 Larger than 20 micron and the     
 particles impact in the mouth and    
 throat.  
 Smaller than 0.5 micron and they are   
 not retained. Some portion of the  
 dose may be swallowed. 
Topical or 
Transdermal 
The local effect (e.g., ear drops, eye 
drops or ointment, antiseptic 
creams and ointments, sunscreens). 
The systemic effect (e.g., 
nitroglycerin ointment). 
Absorption is quite slow. 
Transdermal patches can provide 
prolonged or controlled drug 
delivery. 
There may be some skin irritation. 
Drug absorption will vary by site of    
administration, skin condition, age,   
and gender. 
Absorption is better with low dose,   
low MW, lipid soluble drugs. 
 
 
Source: Understanding Pharmacology for Health Professionals, Fourth Edition, by Susan      
M. Turley, 2010. http://wps.pearsoncustom.com/wps/media/objects/10490/10742713/HC115_Ch04.pdf  










2.5 Structure of the Skin 
The skin is the largest organ in the human body. The best approximation that a material 
scientist could make of the skin is of a multi-component/compartmental membrane. 
           This membrane consists of three separate and distinct components; the superficial, 
thinner portion is the epidermis. The subsequent thicker part is the dermis, and the deeper 
part, which connects to the blood vessels, muscles, and bones, is the hypodermis as seen in 
Figure 2.15. 
 
Figure 2.15 Skin structure 
Source: Subcutaneous tissue, http://en.wikipedia.org/wiki/Subcutaneous_tissue. Accessed      















The hypodermis, shown in Figure 2.16, is the skin’s innermost/deepest component that 
consists of adipose and areolar tissue along with nerves, blood, and lymph vessels. It is the 
component that surrounds muscles and bones. 
 
 
Figure 2.16 Hypodermis structure (200X Magnification) 













2.4.2 Adipose Tissue 
Adipose tissue consists of cells designed to store fat that could be released as fuel to the skin 
and surrounding tissues as required. Their structure consists of lipids surrounded by a 
cytoplasmic membrane as seen in Figure 2.17. 
 
 
Figure 2.17 Adipose tissue/cells (320 x 240 enlargement) 
Source: Adipose Tissue, Tissues of the Human Body, McGraw Hill. 
http://www.mhhe.com/biosci/ap/histology_mh/adiposfs.html. Accessed on November 30, 2014. 
 
       The cytoplasmic membrane releases the lipids upon mechanical stress, thus, enabling the 








2.4.3 Areolar Tissue 
Areolar tissue, also known as loose connective tissue, is a randomly arranged series of fibers 
that creates a mesh surrounding blood, lymph vessels, and organs, thus, making it the ideal 
cushioning agent providing a greater degree of protection as seen in Figure 2.18. 
 
 
Figure 2.18 Areolar tissue (600 x 381 magnification) 
Source: http://www.anatomybox.com/wpcontent/uploads/2012/01/AreolarConnectiveTissueSkin.jpg.  
Accessed on November 30, 2014 
2.4.4 Dermis 








Figure 2. 19 Dermis 
Source: http://www.webmd.com/skin-problems-and-treatments/picture-of-the-skin 
             Accessed on November 30, 2014. 
 
         It is divided into two adjacent substrates or layers. The one next to the epidermis is 
called the papillary region and the deeper thicker layer, known as the reticular dermis, is 







Figure 2. 20 Dermis layers 
Source: http://droualb.faculty.mjc.edu/Lecture%20Notes/Unit%201/FG04_07.jpg. Accessed on    
November 30, 2014. 
 
          The papillary layer lies directly beneath the epidermis and connects to it via papillae 
(i.e., finger-like projections). The reticular layer of the dermis contains crisscrossing collagen 





Figure 2. 21 Papillary and Reticular layers (384 x 288 magnification) 
Source: http://rubred.files.wordpress.com/2013/05/161_dermis.gif. Accessed on November 30, 2014. 
 
         Papillary region (i.e., the upper layer immediately beneath epidermis) consists of 
areolar connective tissue containing thin collagen and elastic fibers, dermal papillae 
(including capillary loops), corpuscles of touch and free nerve endings. The papillary region 
is the superficial part of the dermis. The surface area of the papillary region is greatly 
increased by small fingerlike projections called dermal papillae. Some dermal papillae 
contain tactile receptors called corpuscles of touch or Meissner corpuscles. These are nerve 
endings that are sensitive to touch. Also present in dermal papillae are free nerve endings, 







The reticular region is the deeper part of the dermis. In this region, bundles of collagen fibers 
are interlaced in a net-like manner. Adipose cells, hair follicles, nerves, sebaceous glands, 
and sweat glands occupy the space between the fibers. A combination of collagen and elastic 
fibers in the reticular region is responsible for providing the skin with strength, extensibility, 
and elasticity. 
           Fibroblasts provide the structural framework for many tissues and have a critical role 
in wound healing. They are also responsible for synthesizing the dermal proteins as seen in 
Figure 2.22.  
 
 
Figure 2. 22 Fibroblasts (640 x 530 magnification) 
Source: http://www.pathologyoutlines.com/images/softtissue/02_28C.jpg. Accessed on November 30, 2014   
         




Collagen is composed of a triple helix, which generally consists of two identical chains (α1) 
and an additional chain that differs slightly in its chemical composition (α2) (Figure 2.23).(15) 
The amino acid composition of collagen is atypical for proteins, particularly with respect to 




Figure 2. 23 Tropocollagen structure 






The epidermis encompasses different stages of cellular differentiation, gradual loss of 
nuclear material, and accumulation of keratin proteins. These stages are physically four 
layers:  
- Stratum Basale 
- Stratum Spinosum 
- Stratum Granulosum 
- Stratum Corneum 
but there are a few areas where exposure to friction is greatest (e.g. fingertips, palms, and 





Figure 2. 24  Layers of the epidermis: (B) Stratum Basale, (S) Stratum Spinosum, (G)      
Stratum Granulosum, and (C) Stratum Corneum (497 x 311 magnification) 
 
Source: http://pharmaxchange.info/press/wp-content/uploads/2011/03/Figure-6-Layers-of-epidermis.jpg. 





               These layers are stratified in a sequential order as shown in Figure 2.25. 
 
 
            
Figure 2. 25 Schematic image showing a section of epidermis with labelled layers 
             











2.6.1 Stratum Corneum 
This layer is composed of 10 to 30 polyhedral, anucleated corneocytes, which is the final 
phase of keratinocytes differentiation. Palm and soles have most of these layers.       
           Corneocytes are surrounded by a protein sheath (cornified proteins) filled with water-
retaining with keratinized proteins, attached together through corneodesmosomes and 
surrounded in the extracellular space by stacked layers of lipids.[10] Most of the barrier 
functions of the epidermis localize within this layer.[11] 
 
2.6.2 Stratum Lucidum 
This is a clear/translucent layer that is only present in palms and soles. This layer is present 
only in those areas that are prone to friction (i.e. in thick skin). It consists of a large amount 
of keratin and thickened plasma membrane. The layer is made of three to five layers of 
flattened dead keratinocytes. 
 
2.6.3 Stratum Granulosum 
This is the middle layer of the epidermis. It consists of a protein called keratohyalin, which 
converts to no filaments into keratin. This layer consists of three to five layers of flattened 
keratinocytes. Also present in the keratinocytes are membrane enclosed lamellar granules, 
which release a lipid-rich secretion. This secretion fills the space between cells of stratum 
granulosum, stratum lucidum, and stratum corneum. They act as a water repellent sealant that 





2.6.4 Stratum Spinosum 
This is the layer above the stratum basale. It provides both strength and flexibility to the skin. 
This layer consists of 8 to 10 layers of keratinocytes. The Keratinocytes become connected 
through desmosomes and start to produce lamellar bodies, from within the Golgi, enriched in 
polar lipids, glycosphingolipids, free sterols, phospholipids and catabolic enzymes.[4] 
Langerhans cells, immunologically active cells, are located in the middle of this layer. 
 
2.6.5 Stratum basale 
 This layer is mainly composed of disseminating and non-disseminating keratinocytes, 
attached to the basement membrane by hemidesmosomes. Melanocytes are present, 
connected to numerous keratinocytes in this and other strata through dendrites.  
Within these layers, different types of cells with specific functionality are present as seen in 









Figure 2.26 Types of cells present within the epidermis layers 
Source:https://bohone09.wikispaces.com/file/view/Picture_3.jpg/87308785/619x422/Picture_3.jpg. Accessed 




2.6.6  Merkel Cells 
Merkel cells are also found in the stratum basale with large numbers in touch-sensitive sites 
such as the fingertips and lips. They are closely associated with cutaneous nerves and seem 
to be involved in light touch sensation.[10]  
             Merkel cells are used as sensory receptors for light touch. They are usually located in 
the deepest layer of the epidermis. These cells are in contact with the flattened process of a 
sensory neuron structure called a tactile disc. Merkel cells and tactile discs together detect 
different aspects of touch sensation. Figure 2.27 shows the schematic representation of a 
Merkel cell-neurite complex as observed ultra-structurally. This diagram depicts (1) a 




intranuclear “rodlet,” and membrane-bound dense core granules (G) and (2) a mitochondria-
rich myelinated axon (A) with postsynaptic thickening of its terminal membrane. 
 
 
Figure 2. 27 Merkel cells 
Source: http://www.derm101.com/wp-content/uploads/ac01g069.jpg. Accessed on November 30, 2014 
 
2.6.7  Langerhans Cells 
Langerhans cells arise from red bone marrow and migrate to the epidermis. They participate 
in immune response against microbes that invade the skin and these cells are easily damaged 






Figure 2. 28 Langerhans cells (1818 x 1228 magnification) 
Source: http://upload.wikimedia.org/wikipedia/commons/2/2e/Dendritic_cells.jpg. Accessed on November 30, 
2014. 
 
2.6.8  Keratinocyte 
They make up 90% of the epidermal layer of the skin and they produce the protein keratin. 
The protein protects the skin and underlying tissues from heat, microbes, and chemicals. It 







Figure 2. 29 Keratinocytes as seen under a microscope 
Source: http://pharmaxchange.info/press/wp-content/uploads/2011/03/Figure-2-keratinocytes- as-seen-under-a-
microscope.jpg. Accessed on November 30, 2014. 
 
2.6.9  Melanocytes 
Melanocytes make up 8% of the epidermis. It produces the pigment melanin, which 
contributes to the color of the skin and absorbs the damaging ultraviolet light. Figure 2.30 
shows the structure of Melanocytes. 
 
 
Figure 2.30 Melanocytes 






2.6.10  Macrophages 
Macrophages are white blood cells, also called big eaters, as their role is to digest and eat 
(phagocytocis) cellular debris and pathogens. They are about 21 micrometers (0.00083 in) in 




Figure 2.31 Macrophage 
Source: http://www.phartoonz.com/wp-content/uploads/2010/11/leukocyte_immunity_Macrophage.png. 





2.7 Routes of Drug Entry unto the Skin 
There are three paths that drug actives can penetrate the skin. These paths are known as the 
intercellular, transcellular, and follicular routes (17). This is shown in Figure 2.32. 
          
Figure 2.32 Delivery Skin Routes 
Source: http://biomed.brown.edu/Courses/BI108/BI108_2003_Groups/Transdermal/Skin/SkinPerm.htm    
Accessed on December 1, 2014. 
 
          This is also well known as the “brick and mortar” model. The brick is the protein 
where trans-cellular penetration occurs whilst the lipid is the mortar in which the intercellular 





          
Figure 2. 33 Brick and Mortar 
Source: Understanding the causes of skin disease, Health and Safety Executive,   
 http://www.hse.gov.uk/skin/professional/causes/understand.htm. Accessed on December 1, 2014. 
 
2.8 TDD Techniques 
The delivery of drugs is the basis for the improvement in patient health. The usual route is to 
develop such deliveries to be administered orally for improved patient compliance.  






1. Irritation of the GIT. GIT is the chemical interaction between the active drug and 
mucosa membranes of the gastrointestinal track comprised of the region from the 
upper esophagus to the duodenum region of the intestine that can create discomfort 
and potential chemical erosion of the membranes. In turn, this can make the patient 
either skip or discontinue the use of the treatment, thus, making the patient no longer 
abide by the therapeutic regime set by the physician, thus, effectively delaying the 
sought after benefits. This is perhaps one of the major issues encountered by 
physicians when prescribing orally delivered therapies. 
2. First pass metabolism, or pre-systemic metabolism, is defined as the condition in 
which the bio-available concentration of the drug is significantly reduced when 
passing through the liver before it is in contact with the bloodstream. [1, 2]  Therefore, 
in order to overcome this, the concentration of the drug must be substantially 
increased in order to be effective, thus, ensuring that the patient receives the correct 
amount. However, as seen in Figure 2.34(14) this can create situations during which 
the drug is rarely at the desired therapeutic level (TL). This can be either fully below 
or above the TL, thus, practically rendering the treatment inadequate or dangerous. 
3. Low patient compliance - For any treatment to be effective, the patient must adhere to 
the regime prescribed by the physician. Aside from the influence of GIT along with 
busy schedules, people very often skip doses, thus, rendering the designed procedure 





      
 
Figure 2.34 Hypothetical blood level pattern from a conventional multiple dosing            
schedule and the idealized pattern from a transdermal controlled release system. 
 
   Source: Falcone, R., Jaffe, M. and Ravindra, N.M.,  New screening methodology for selection of  
   polymeric matrices for transdermal drug delivery devices, Bioinspired, Biomimetic and  
   Nanobiomaterials, Volume 2 Issue BBN2, p. 65 – 75, 2013  
 
         TDDs are passive drug delivery systems that provide a constant active drug flow to the 
patient through the skin.  
          The advantages of leveraging TDD against any other non-oral delivery (NOD) can be 
summarized as follows:  
 complete avoidance of the first pass metabolism through the liver, 
 non-GIT incompatibility, 
 lower side effects or better plasma – concentration time profiles,  
 greater predictability and long period of drug activity, 
 increased patient compliance, 
 enhanced therapeutic efficacy, 




 increased flexibility in ending protocol by simply removing the source, and 
 Non-invasive and ease of implementation/use. 
 
2.9 Transdermal Patch Design 
Transdermal patches (TDDP) are systems consisting of several components that are 
specifically designed for different applications as shown in Figure 2.35(18). 
 
          
Figure 2.35 Types of transdermal patches 
Source: Sachan, R. and Bajpai, M., TRANSDERMAL DRUG DELIVERY SYSTEM: A REVIEW,  
International Journal of Research and Development in Pharmacy and Life Sciences, Vol.3, No.1, pp 748-765, 









         The basic TDDP working release mechanism is shown in Figure 2.36. 
 
           
Figure 2.36 TDDP release mechanism 
Source: http://www.hisamitsu.co.jp/english/company/operations/tdds.html. Accessed on      
              December 2, 2014 
 
           Designing transdermal patches is a three-step process. Step 1 involves finding the 
physicochemical compatibility between the active drug and polymers used in the films. Step 
2 involves the film fabrication. Step 3 is the in-vitro active drug release evaluation where the 
cumulative release is then plotted against time as shown in Figure 2.34 where the diffusion 
coefficient is found from the slope. This is a trial and error method, which is time 
consuming. Although, with all the advantages that TDDs can offer, the methodology used 
has created several incidents in which the safety and design have been put to question as seen 





A generally accepted set of selection rules, for materials, in TDD patches were   
suggested by Williams (19).  These can be summarized as follows: 
1. Selection of a good drug candidate: 
a. molecular size limit not to exceed between 300-500 Da., 
b. active release of drug in the range of 1 mg/cm2/day, 
c. log P(octane / water) = 1 – 3.5, 
d. aqueous solubility > 100 µg / ml, 
e. daily dose < 10 mg / day, 
2. maintain optimum drug saturation, keeping in mind that the thermodynamic activity 
is the key driving force instead of concentration, 
3. drug flux can be optimized by formulation design, 
4. use of vehicles/solvents with good partition coefficients can increase dose delivery; 
and 
5. Drug molecules will continue to move after penetrating the skin. 
         The most difficult part is to create a TDD patch that will lead to the desired dose 
delivery. In addition to Williams’ rules, most research work involves an empirical trial and 
error process to identify the polymeric matrix that will release the drug at the desired 
therapeutic levels.  Drug delivery is determined by the permeation rate in the patch; the 
critical factor in the permeation rate is the diffusion coefficient of the actives through the 




CHAPTER 3                                                                                                                                                   
DIFFUSION 
                                                        3.1 Definition 
Diffusion is defined as the solute displacement in solids from high concentration to low 
concentration zones, ending with equal solute distribution. Diffusion can be considered as a 
process resulting not from a forced action, but more as a result of the random distribution of 
solute atoms (See Figure 3.1) (20, 21). 
 
 
Figure 3.1 Fick’s self-diffusion 
Source: Karger, J., Ruthven, D. M. and Theodorou, D. N., Diffusion in Nanoporous Materials,   
http://www.wiley-vch.de/books/sample/352731024X_c01.pdf. Accessed on December 5, 2014. 
 
          This process was originally evaluated by Fick (22), who described this phenomenon 




          (3.1) 
where, 
C = active concentration, 
t = time, 
x = traveling distance, 
and D = diffusion coefficient. 
Equation (3.1) is better known as Fick’s Second Law, which takes into account the non-
uniformity solubility of the diffusing solute into the matrix within which it is encased.  
          There are presently two models that describe the diffusion in solids and in polymeric 
matrices in particular. The molecular model analyzes how the diffusant or solute moves 
along the polymer chains with the correspondent molecular interactions or forces. The free 
volume model approximates the relationship between the diffusion coefficient and the free 
volume that is present in the polymeric matrix.  
3.2 Definition of Molecular Models 
Molecular models assume that small voids or oscillating “cavities” are within the polymeric 
matrix. When the matrix is in equilibrium, these “cavities” could be defined as definite 
distribution centers inside the matrix. Solute diffusion is highly dependent on the number of 
available cavities that are large enough to allow the solute molecular movement throughout 
the matrix. A solute molecule could be in a cavity that is large enough for it to move (jumps) 
into the nearest available cavity as soon as it gathers the minimum amount of energy. This is 







Figure 3.2 Molecular mobility through voids / oscillating cavities 




Figure 3.3 Diffusion motion  
Source: 
http://amisca.chem.itb.ac.id/download/Fundamentals%20of%20Materials%20Science%20and%20Engineering









      In Figure 3.3, the numbers represent the following: 
1. Neighboring atoms exchange sites, 
2. Ring mechanism, 
3. Vacancy mechanism, 
4. Direct interstitial mechanism, and 
5. Indirect interstitial mechanism. 
The minimum amount of energy is easily experimentally demonstrated by the modified 
Arrhenius seen for diffusion coefficients and shown in equation (3.2) (22) and Figure 3.4 
D = Do exp (-Ea/RT) (3.2) 
where, 
Ea = apparent activation energy of diffusion, 
Do = a pre-exponential constant, 
R = the gas constant, and 





Figure 3.4 Mechanism steps and activation energies 
Source: Torres, L.L., Diffusion in Materials (PPT),  
http://www.slideshare.net/luiscobaya/diffusion-in-materials. Accessed on December 6, 2014. 
 
          Meares (23, 24) suggested a molecular model for polymeric matrices in which the 
activation energy of diffusion was directly related to the square of the solute/diffusant 
diameter. Moreover, the initial diffusion step was related to the energy required to create a 
cylindrical path within the polymeric chains where the solute was able to move or jump from 
one position to the next. This was defined as: 
Ed = (π/4) σ2 NA λ (CED) (3.3) 
where, 
Ed is the activation energy of diffusion, 




NA is the Avogadro number, 
λ is the diffusional jump length,  
and CED is the cohesive energy density of the polymer. 
It is relevant to indicate that Meares assumes the following: 
1. The solute is solely spherical and that no other shapes are possible; 
2. No polymer-solute interactions exist.  
          Brandt (25) suggested a different approach that employed a more succinct definition of 
the matrix structure to estimate Ed. The approximation is based on the assumption that 
diffusion is active when two or more polymer chains are symmetrically bent, thus, enabling 
direct routing for the solute. In turn, this promotes a synergistic process among neighboring 
polymer chains, which is deemed essential for solutes that unable movement within the 
existing inter-chain spaces.  
           The activation energy, Ed, is defined as the sum of an intermolecular contribution, Ei, 
and an intermolecular contribution, Eb. 
Ed = Eb + Ei (3.4) 
          Ei is the result from the interaction between the internal resistance and the chain 
bending and Eb is defined as the repulsion of the bent chain segment due to its neighboring 
chains.       
            When applying this model to experimental results, it was found that Ed had a 
nonlinear dependence on the solute collision square diameter. 
             This is contradictory to the model of Meares, which shows a linear dependence of Ed 
on σ2. Brandt’s model also suggests that the activation energy is dependent on the molecular 




diffuse throughout the existing free volume within the polymer chains. Brandt found that Ed 
was not proportional to the cohesive energy density of the polymer. The diffusion process 
could then be described in terms of polymer chain energy displacements where the matrix 
and solute interactions could be considered non-significant. 
        A different approach was proposed by DiBenedetto and Paul (26) in which the nonlinear 
interaction of Ed with σ2 was better predicted. Yet, it ignores any interactions that can exist 
between the matrix and the solute. In their approximation, the polymeric matrix can be 
assumed as a homogeneous continuous entity that consists of Avogadro’s number of 
“principal components.” A principal component is defined as a polymer repeat unit that 
comprises a cylindrically symmetric potential field formed by its four nearest-neighbors.  
          The activation energy is defined as the potential energy difference between the 
“normal” state in which the four neighboring components are at equilibrium positions, and 
the “activated” state in which they are separated by a cylindrical void. This implies that the 
activation energy can be described as the potential energy difference in the partial breaking 
of the bonds between the four principal components. This concept is very similar to the 
cohesive energy density as described by Meares.  
          A solute molecule is assumed to exist within a void or cell created by the four parallel 
polymer components. Coordinated rotations and vibrations of these components can result in 
another cylindrical void adjacent to the solute molecule. This is followed by the displacement 
of the solute molecule into the nearest newly created cylindrical void.     
          The energy required to compress the surrounding polymer is ignored. This approach 
does not take into account the complexity of the matrix and the molecular shape and size of 




3.3 Free Volume 
Free volume can be simply defined as the difference between the specific volume and the 
calculated molecular volume  
Vf = Vs – Vcm                                                                                                                (3.5) 
A graphical representation of the Free Volume concept is shown in Figure 3.5. 
 
Figure 3.5 Free Volume Model 
Source: Free Volume, Cambridge University, http://www.doitpoms.ac.uk/tlplib/glass-               transition/free-
volume.phpl. Accessed on December 2, 2014. 
 
          Eyring(27) suggested that the molecular motion in any polymeric matrix is proportional 
to the presence of molecular cavities that are creating voids within the structure. In other 
words, when the solute molecule travels to a void, the void will trade places with the solute 






Figure 3.6 Eyring Molecular Model 
Source: http://www.owlnet.rice.edu/~ceng402/proj02/beckys/. Retrieved on December 16, 2014 
 
         For a solute molecule to move from one position to the next, a critical void volume 
must be in place before any changes or displacement can take place. This implies that solute 
motion will not take place if these voids are not present. These voids as a whole could be 






Figure 3.7 Free volume 3D representation 
Source: https://www.xsede.org/documents/234989/378230/XSEDE12-willmore.pdf. Retrieved on  
December 16, 2014. 
 
           In general terms, the free volume of a polymeric system can be stated as the volume of 
the one at a particular temperature of interest less the one of the same system that would exist 
at absolute zero.  
           Therefore, free volume can be seen as creating holes where solutes can diffuse and 
pass through. Free volume can be seen as the overall contribution of all the entities present in 
the matrix, solute and voids.  Figure 3.8 shows the volume disposition in a rubbery matrix as 





Figure 3.8 Schematic representation of volume disposition in a rubbery matrix as a     
function of temperature 
 
Source: Fig. 2 in J. L. Duda and J. M. and Zielinski, Ch. 3 in “Diffusion in Polymers”, P. Neogi,  
ed., M. Dekker, N. Y., 1996. https://www.uakron.edu/dotAsset/483661.pdf. Accessed on  
December 2, 2014. 
 












3.4 Free Volume Models 
The difference between molecular and free volume (FV) models is that diffusion is not 
considered as a thermal dependent process in FV models. FV models assume diffusion as a 
random renormalization of free volume voids within the polymeric matrix. 
          This assumption was first suggested by Cohen and Turnbull. (27) They originally 
thought that this approach was only suited for liquids that could be visualized as the uniform 
aggregation of hard spheres. From the Cohen and Turnbull viewpoint, the hard sphere 
molecules would compose of an ideal liquid that exists in empty spaces created by the 
nearest neighbors. In other words, the total volume can be seen as two volumetric 
compartments, one occupied and the other free. Although the sphere does not have the ability 
to migrate within its space unless a thermal natural fluctuation would create a gap (vacancy) 
next to its enclosure, this gap must be sufficiently large enough that it would enable the 
displacement of a spherical molecular entity. The diffusion or molecular movement is 
deemed successful when the empty space left behind by a molecule is then filled by the 
adjacent molecule. Instead of creating gaps by the physical displacement of the nearest 
neighbors, this is a mechanical and not translational motion that does not need a set energy 
level to surmount an activation energy barrier. This is indicated in the activation energy 
approach of Pace and Daytner (28). Molecular migration is solely based on the constant 
rearrangement of free volume entities inside the liquid. The mathematical description of the 
free volume entities could be better described as a probability function in which the diffusion 
coefficient can be assumed to be proportional to the probability of locating a gap of volume 
V* or larger, and could be written as: 




where the molecular self-diffusion coefficient,  V*, is the lowest gap size volume that a 
molecule can migrate, V is the specific volume and γ is a numerical factor between 0.5 and 
1.0, to account for the overlap between free volume entities such as the free space (gap) 
shared by a neighboring molecule.  A is defined as the proportionality constant that is 
associated with the gas kinetic energy. This clearly indicates that the molecular self-diffusion 
coefficient is an exponential function of the ratios of the molecular size of the diffusing 
solute to the free volume per molecule of the matrix. Considering the self-diffusion of a 
solute in a binary type matrix, equation (3.6) can be rewritten as follows: 
D1 = D01 exp[-γ V1*/VFH] (3.7) 
V1*  = critical molar free volume needed for any displaced singularity of species 1    
          to move,  
VFH = free volume per mole of all individual moving solute units in the matrix, 
and D01 = temperature – independent constant. 
          While Cohen and Turnbull defined the moving solute unit as a single hard-sphere 
molecule that undergoes diffusion, this is not the case when dealing with polymeric systems 
where the matrix consists of a macromolecular mixture. Yet, an individual solute molecule 
can be made of several diffusing units that are united by covalent bonds. Free volume gaps 
that can easily accommodate whole polymeric entities will not readily form.    
          Rather, solute migration is seen as a series of continuous jumps of small parts along 






Figure 3.9 Cohen and Turnbull graphical representation 
Source: http://www.scl.kyoto-u.ac.jp/~kanaya2/kanaya_lab~2009/e-g-j.htm. Accessed on  
December 4, 2014 
 
          This could be further convoluted when low molecular weight solutes, having sufficient 
size and maneuverability, are able to move in a disposition similar to what is seen in 
polymeric systems that consist of the use of several components of the molecular chain(29,30).  
Generalizing the Cohen and Turnbull theory to depict the motion in binary systems, where 
the molecular shape and size of the solute must be included, Vrentas and Duda(31) introduced 
the following relationships: 
 (3.8) 
VFH = specific gap free volume of a solute with a weight fraction ωi of species i, 
Mij = molecular weight diffusing units  (i = 1 or 2). 




D∞ = Do exp [ -  ] exp [ - ] (3.9) 
where,  
            D∞ is the infinite dilution diffusion coefficient, 
Do  is a constant pre-exponential factor, 
E* is the energy that a molecule must possess to overcome attractive forces from   
     the surrounding neighboring entities, 
V* is the specific free volume space of polymer needed for molecular jump, 
Vf  is the space free volume provided by the polymer for solute to diffuse, 
and ξ is the ratio of the solvent critical molar volume jumping unit to the polymer  
   jumping unit. 
         Then, combining equations (3.7), (3.8), and (3.9), an expression is derived for the 
diffusion  of a solute in a polymeric matrix that can be expressed as: 
     (3.10) 
where, 
Ws is the weight percent of the solute – drug active present in the matrix, 
Vs is the volume of the solute or drug active in this case, 
Wp is the weight percent of the polymer – matrix component, 
Vp is the volume of the polymer matrix where the active drug is  
embedded, 
ξ is the ratio of the solvent critical molar volume jumping unit to the   
polymer jumping unit, 
VFH is the free volume, 




forces from the surrounding neighboring entities, 
R is the Boltzmann’s constant, 
and T is the temperature at which the diffusion is taking place. 
            If  is defined as the specific hole free volume in a block copolymer and 
solute mixture, then, the available free volume for molecular diffusion/transport 
could be written as: 
 
  (3.11) 
where, 
ωi is the weight fraction of component i (i =1 or 2), 
W2a and W2b are the weight fractions of the blocks A and B within the  
 copolymer, 
M1j, M2ja and M2jb are the molecular weights of the jumping unit for the  




ξijk is the ratio of solvent to polymer jumping units, 
Mij is the molecular weight of the solute, 
Mijk is the molecular weight of the block copolymer, 
V*i is the specific volume of the solute,  
and V*i k is the specific volume of block k (k = a or b) in the copolymer at 0 K.  




  (3.14) 
          where, V2k (k is for either a or b) is defined as the specific volume of block k in the 
copolymer at 0 K. In the event that the polymeric system is a homo-polymer, then W2a = 0 
and W2b = 1 and equation (3.14) is reduced to the original system for solute self-diffusion in 
a homo-polymer in equation (3.10). 
3.5 Effect of various physical effects on the Diffusion Coefficient 
3.5.1. Effect of Molecular Radius 
Several researchers have shown the influence of molecular size on the diffusion coefficient. 
This was originally shown by Einstein and Stokes. They assumed an ideal solution, in which 
there is an inverse proportionality between diffusion and molecular size defined by the solute 
radius: 
 
   (3.15) 
where, 
KB is the Boltzmann’s constant, 
µ is the solute viscosity, 
and R0 is the solute molecular radius. 
R0 can be estimated from the volume V, which is defined as:  
V = (4/3)π R03 (3.16) 
and 




            Defining m as solute mass and ρ as solute density, 
M = Mw / NA (3.18) 
where,  
Mw is the solute molecular weight, 
and NA is Avogadro number, 
Substituting (3.18) in (3.16), 
(4/3π R03) = Mw/NAρ (3.19) 
Then, R0 can be defined as: 
  (3.20) 
R0 is also known as hydrodynamic radius, Rh. Rg is defined as the mass weighted 
average distance from the core of a molecule to each mass element in the molecule. The 
radius of gyration of a molecule is the radius of a thin ring that has the same mass and 
moment of inertia as the molecule when centered at the same axis.  Figure 3.10 shows the 













Figure 3.10 Comparison between radius of rotation, hydrodynamic radius, radius of 
                     gyration, and mass radius  
 
Source: http://www.imbb.forth.gr/people/aeconomou/pdf/hydrodynamic_radius.pdf. Retrieved on December 2, 
2014. 
 
There are different relationships for spheres, rods, and coils that can be expressed as (32): 
Rsphere = ksD / 2                                                                                             (3.21) 
Rrod = ksL / 2                                                                                                          (3.22) 
Rcoil = (k2s2r2) / 2                                                                                              (3.23) 
where, 
D = diameter of sphere, 
L = length of rod, 
k and s = constants, 




The radius of gyration (Rg) is usually calculated from static scattering measurements and the 
hydrodynamic radius (Rh) also known as the Einstein-Stokes radius or equivalent spherical 
radius.  It can be determined by dynamic light scattering or other diffusion measurements.  
For instance, a solid sphere can yield a value of: 
Rg / Rh = √3/5 ≈ 0.77                                                                                     (3.24) 
Rg = 0.77 Rh                                                                                                                                                 (3.25) 
DRh  /  DRg  (1/Rh ) / (1/Rg)                                                                         (3.26) 
DRh  /  DRg  = Rg/Rh                                                                                                                               (3.27) 
DRg =  DRh  / 0.77                                                                                            (3.28) In 
this case, the Rg / Rh ratio could be estimated as: 
Rg / Rh ~ 1.22 ln (L/D)                                                                                       
(3.29) 
where, L/D is the aspect ratio of the longitudinal and latitude axes of the molecule 
and this can be achieved by a slender rod geometry (Appendix E) and,  
DRg =  DRh / 1.22 ln (L/D)                                                                                (3.30) 
Tande et al noted that Rg and Rh can be determined in larger molecules as a power 
law relationship to the molecular weight. This is not the case with molecules having lower 







3.5.2 Effect of Molecular Shape 
However, from 3D molecular modeling, not all molecules will have spherical shapes as seen 
for the nicotine molecule (Figure 3.11). 
 
 
Figure 3.3 3D nicotine model 
Source: http://commons.wikimedia.org/wiki/File:Nicotine-3D-vdW.png. Retrieved on November  
23, 2014. 
 
 In the original work of Vrentas and Dudas, ξ is defined as the ratio of the molar 
volume of a solute jumping unit to the molar volume jumping unit. This is based on the 
assumption that the solute will jump in single units and flexible long chain solutes would 
exhibit segment-wise movement. A method for estimating ξ was developed by Vrentas et al.   
Moreover, this approach also assumes that the average hole free volumes within the polymer 
and solute jumping units would be different. Nobrega et al. suggested that, for solutes that 





                                                                            (3.31) 
  
3.6 Theoretical Background 
The known solution for the equation of the diffusion coefficient, for a planar surface, a 
TDDP in this case, when the diffusion coefficient is constant, was shown by Crank (20, 21) to 
be: 
 (3.32) 
            In most cases, TDDP systems are designed to deliver, under non-steady state, where 
the following boundary conditions must be in place. Therefore, equation (3.32) can be further 
simplified as: 
 (4) when                                                      (3.33) 
where, Mt is the active released from the patch at time t, M∞ is the initial concentration of the 
active in the patch, D is the diffusion coefficient, and t is the time of release. 
             Diffusion phenomena in TDDS must be modeled as small molecule mobility in the 
macromolecular matrix. This along with the backbone chemistry are perhaps the main 
influential factors. Yet, in these types of systems, the mobility is considerably influenced by 
temperature and concentration. These conditions are mostly pronounced near the glass 
transition temperature (Tg) where it has been shown that an increase of 1% of the solvent 
weight fraction in the matrix can effectively increase the diffusion (D) by three orders of 




Therefore, significant experimentation is the key to obtaining satisfactory approximation, as 
well as optimization of results for this particular situation that is actually governed by 
molecular transport.  However, this requires significant trial and error process in determining 
the right matrix that will provide the release rate of the solute into the skin to achieve the 
desired therapeutic effect.  
             This approach does not take into account the complexity of the matrix and the 
molecular shape and size of the active; thus, free volume concept must be considered in the 
polymer in the TDDS case.  From this, it could then be assumed that free volume is the key 




          CHAPTER 4                                                                              
EXPERIMENTAL RESULTS 
 
                                            4.1 Experimental Methods 
Nicotine patches were used for this evaluation for two key reasons: 
1. Nicotine patches have been one of the most predominant and successful technologies 
used to control smoking cessation. 
2. Nicotine patches are the most commercially sold TDD patches in the market. 
          The first step was to generate a nicotine ultraviolet absorption chart by means of 
setting a master curve. This master curve was determined from ultraviolet readings of 
different nicotine concentrations in a normal saline solution (0.90 % w/v of sodium chloride 
or about 300 mOsm/L or 9.0 g per liter).(33) The reason for using such a system is because the 
osmolarity of normal saline is a close approximation to the osmolarity of NaCl in blood. 
Different nicotine concentration solutions were made and ultraviolet absorption 
measurements were performed using a Genesys VI ultraviolet spectrophotometer.  
           An ultraviolet absorption versus nicotine concentration chart was generated in which 
the plots were fitted by means of regression, thus, resulting in a master curve having a linear 
characteristic with R2 = 0.9778, which was deemed acceptable to use as a master calibration 
curve.  This is shown in Figure 4.1.  The nicotine was purchased as a 99% active 






             
Figure 4.1 Nicotine ultraviolet absorption chart 
          The next step was to determine the release from the nicotine patches. Samples were 
purchased from commercially available nicotine patches sold over the counter in the US. 
These patches consist of three layers: (a). backing to provide mechanical support as well as 
protection to the release layer from environmental conditions, (b). a nicotine reservoir 
containing a layer that includes the adhesive, and (c). the PET disposable piece that is 










Figure 4.2 Diagram of a typical commercial nicotine patch [20] 
Source: TRANSDERMAL A NOVEL DRUG DELIVERY SYSTEM  
http://www.pharmatutor.org/articles/transdermal-novel-drug-delivery-           
system?page=0,1. Retrieved on December 5, 2014. 
           
         The patch used in these experiments is the Nicoderm CQ, 7 mg daily dosage patch. The 
physical measurements of the patch is 1 inch square with a thickness of 0.229 cm. where the 
actual thickness of the diffusion layer is estimated to be approximately 0.0113 cm. 
           Patches from the same lot were assembled on top of vertical static Franz cells (Figure 
4.3) and were placed in direct contact with the saline solution. These patches were secured in 










Figure 4.3 Franz static cell components (34) 
Source: http://www.permegear.com/franzcellcomponents.gif. Accessed on December 7, 
2014. 
 
          The nicotine patch was placed between the top of the cell and the body of the cell 
(Figure 4.4) in contact with a normal saline solution which is kept at a constant temperature 





Figure 4.4 Fully assembled typical Franz static cell 
Source: http://www.permegear.com/6G01000520.jpg. Accessed on December 7, 2014. 
 
        Measurements of the samples were taken at 1 hour intervals for the first 8 hours and 
then the last measurement after 24 hours. Then the amount released was estimated as a 
function of the measured concentration by ultraviolet spectrophotometry and the volume 
present in the vertical static Franz cell reservoir. This was done in accordance with the FDA 
SUPAC guidelines(35) as well those with Thakker and Chern,(36) Siewert, Dressman, Brown, 
and Shah,(37) Raney, Lehman, and Franz,(38) Marangon, Bock, and Haltner,(39) Lionberger (40), 




Figure 4.5 shows the cumulative amount of nicotine released versus time. 
 
Figure 4.5 Cumulative nicotine release. 
        The diffusion constant was estimated according to the methodology shown by Crank (21) 
and Miller, Oehler, and Kunz (44) as: 
D = 1.467*10-9 cm2/sec 
4.2 Theoretical Approach/Calculation of Diffusion Coefficient D 
          The next part of this section is the theoretical calculation of the diffusion coefficient by 
using the Duda and Zielinski equation (3.14): 





4.3 Estimation of Nicotine Values 
            D0 was obtained from the Einstein-Stokes equation: 
   (4.1) 
KB is Boltzmann’s constant,  
µ is the solute viscosity, 
and R0 is the solute molecular radius. 
R0 can be estimated from the volume V which is defined as (4/3) π R03,  
(4/3π) R03 = m/ρ  (4.2) 
Defining m as (Mw / NA) where, Mw is the molecular weight of nicotine, NA is the 
Avogadro number, and ρ is the density of nicotine at 37ºC, from the literature, the 
following properties are obtained and summarized in Table 4.1 
Table 4.1 Summary of Nicotine Properties 
Property Value 
ρNicotine 1.014 grams /cm3 (45,46) 
Mw 162 grams / mole(45,46) 
µNicotine 2.9037 centipoises or 0.021 grams/cm*sec(45,46) 
Rewriting equation (4.2) gives: 
R0 = 4.062*10-8 cm 
Then, inserting the values for R0, µNicotine into equation (4.1) gives: 
  2.6685*10-5 cm-2 sec-1 





   (4.3) 
 
           The YG equation was chosen because it provided the closest value of  for molecules 
such as nicotine.  To estimate the value of Vs, the critical volume (Vc), accentric factor (ω), 
T, the temperature and critical temperature (Tc) values are needed. Since these values are not 
available from the experimental data, they must be estimated. 
            The acentric factor is estimated from the Pitzer thermodynamic approximations (48-54). 
The values of Tc, Pc, and Vc for nicotine were required to be calculated using the group 
contribution method described by Joback (55, 56). The reason for choosing this equation was 
because of the close approximation found in the estimation of pyridine cyclical structures 
such as nicotine as seen in Figure 4.6. 
 
 
Figure 4.6 Nicotine molecular structure  
Source: http://en.wikipedia.org/wiki/Nicotine. Accessed on December 6, 2014 
 
    (4.4) 




    (4.6) 
To obtain the value of Tc for nicotine, the boiling temperature was required and its 
experimental value was found to be 247ºC or 520.15 K.[33]  Table 3.2 presents a summary of 
the critical properties of nicotine found by using equations (4.4), (4.5), and (4.6). 
Table 4.2 Summary of Critical Properties of Nicotine 
Property Value 
Tc 749.016 K 
Pc 22.6365 atm 
Vc 463.5 cm3/mole 
 The accentric factor for nicotine was found to be: 
        (4.7) 
Using the YG equation, the values of Vs for nicotine, at 37ºC (310.15 K) and 0 K (-
273.15ºC), were calculated and the results are summarized in Table 4.3. 
Table 4. 3 Summary of Volumes of Nicotine @ 310 and 0 K 
Temperature Vs (cm3/mole) Vs (cm3/gram) 
310.15 ºK (37 K) 154.606 0.954 
0 K 94.002 0.580 
 
Now, the corresponding values for nicotine must be estimated. By leveraging the modified 
version of the Doolittle equation for viscosity (56) 





         
and      
 
         K22+T are determined from a non-linear regression using viscosity and temperature 
data (56) 
The results of these calculations are shown in Table 4.4. 






Ξ (Nicotine/Ethylene) 0.797 
Ξ (Nicotine/Vinyl Acetate) 0.577 
          
This gives the value for 
     
as 0.1465 
4.4 Estimation of the values of polymeric matrix components 
As shown by Fierro et al., (57)  
     +  +  





 where, w1, w2a, and w2b are the weight fractions for nicotine, ethylene, and vinyl acetate   
 respectively. 
           The free volume parameters, used in this study, particularly for polymers, are related 
to the constants of the Williams-Landel-Ferry (WLF) (58) equation, C1p and C2p, by the 
following relationships: 
  (4.10) 
  =   (4.11) 
Table 4. 5 Physical properties of ethylene and vinyl acetate units/blocks 
Block Element C1 C2 Tg Wa 
Ethylene 17.44(59,60,61) 51.6(59,60) 237(59) 0.5989(59,60) 
Vinyl acetate 15.6(59,61) 104.4(59,61) 305(59) 0.399(59,60) 
 
 0.0925  if Tg < 295 ºK  (4.12) 
 0.6334  if Tg > 295 ºK  (4.13) 
Then, taking the values from Table 4.5 and inserting them into equations (4.8), (4.9), and 
(4.11), the values for: 
 
  = , and K1i – Tgi                        (4.14) 







Table 4.6 Results Summary 
Block Element 
 
V2 (grams/cm3) K1i/γ K1i - Tgi 
Polyethylene 91.392 1.005 4.825*10-4 -219.56 
Polyvinyl acetate 102.882 0.728(44) 4.33*10-4 -258.2 
 
4.5 Energy Calculations (E*) 
The energy component is calculated from the Tonge and Gilbert (62) equation: 
E*  (4.15) 
δ = (H-RT) 0.5/ v0.5                                                                                                       (4.16) 
                                                                      (4.17) 
where,  
ECOH = m1* ECOH (homopolymer of repeat unit 1) + m2* ECOH (homopolymer of  
            repeat unit 2) (63) (4.18) 
Vcopolymer = m1* V (homopolymer of repeat unit 1) + m2* V (homopolymer of repeat 
unit 2) (63)  (4.19) 
and  
     (4.20) 
           The values of energy for ethylene and vinyl acetate were estimated by Van Krevelen 






Table 4.7 Hildebrand Coefficients for Ethylene and Vinyl Acetate  
Property Ethylene Vinyl Acetate 
ECOH (J/mol) 9,500 25,300 
Vcopolymer (cm3/mole) 32 72 
 
         Then, using the results from Table 4.7 and equations (4.15), (4.16), (4.17), and (4.18), 
the value of energy for the EVA copolymer is found to be 55.66 (cal/cm3).0.5 
          Because no values of Hildebrand Coefficients were found in the literature for nicotine, 
they had to be estimated by using the Fedor’s equation/model (65). This model uses the 
structure to calculate the approximate values of ECOH and volume and this, in turn, yields the 
Hildebrand coefficient. The results are summarized in Table 4.8. 
 
Table 4.8 Hildebrand Coefficients for Nicotine [54] 
Property Value 
ECOH (J/mol) 56,520  
V(cm3/mol) 139.7  
δNIC (cal/cm3) 10.02697  






Table 4.9 shows the summary of the calculated parameters used to calculate the Nicotine 
theoretical Diffusion Coefficient from an EVA polymeric matrix. 
Table 4.9 Parameters used to Estimate the Theoretical Diffusion Coefficient 







Ξ (Nicotine/Ethylene)   0.577 
Ξ (Nicotine/Vinyl Acetate)  0.797  
Vi 0.954 0.728 1.005 
E*   8.0722 
             Then, inserting all the values into (3.14), the diffusion was estimated to be 1.781*10-







Figure 4.7  Cumulative release comparison between Dexp. and Dcalc. 
4.6 Effect of Molecular Radius of Gyration 
In the previous section, the radius of nicotine was estimated to be R0 = 4.062*10-8 cm. If 
assuming a spherical shape, the Rg and Ro are substituted into equation (3.14) where the 
following relationship between DRg and DR0 (also known as Dc) is: 
DRg = DR0 / 0.77                                                                                           (4.21) 
        where, DR0 (calculated diffusion coefficient from section 1) was found to be 1.781*10-9 
cm2/sec; then equation (4.21) is: 
DRg = 1.781*10-9 cm2/sec / 0.77 
and the diffusion coefficient is found to be: 
DRg = 2.313 *10-9 cm2 / sec 
          If assuming a cylindrical shape, then using an analog to equation (4.21), 




and the diffusion coefficient is found to be: 
DRg = 1.028*10-9 cm2 / sec 
Table 4.10 Comparison of Experimental and Calculated Values of the Diffusion 
                    Coefficient using Different Rg Values. 
 
Property Value 
D(experimental)  1.467*10-9 cm2/sec 
DRg (Rg = 0.77 Rh)   2.313*10-9 cm2/sec 
DRg (Rg = 1.732 Rh)   1.028*10-9 cm2/sec 
The calculated results of the diffusion coefficient, using different values of the radius of 
gyration, are shown in Figure 4.8. 
 




4.7 Effect of Molecular Shape 
In the previous section, the ξL values of nicotine and EVA were estimated to be as follows: 
Table 4.11 ξL Values 
ξL (Nicotine/Ethylene)  0.577 
ξL (Nicotine/Vinyl Acetate) 0.797  
          The molecular shape factor (A/B) of nicotine was estimated to be 1.450 (APPENDIX E). 
The ξ values can be estimated using equation (3.31) and APPENDIX E, and the results are 
summarized in Table 4.12. 
Table 4.12 ξ Values 
ξ (Nicotine/Ethylene)  0.7794 
ξ (Nicotine/Vinyl Acetate) 1.2427  
The diffusion coefficient Dξ is estimated to be 2.2887E-09 cm2/sec.   
Table 4.13 Comparison of experimental and calculated values of the Diffusion 
Coefficient using different Rg values. 
Property Value 
D(experimental) 1.467*10-9  cm2/sec 
D (ξ)  2.2887*10-9 cm2/sec 
D (ξL)  1.781*10-9  cm2 / sec 
 






Figure 4.9 Diffusion coefficient comparison between ξ, ξL and experimental values 
          Figure 4.10 shows the effect of the different values of ξ on the results of the Diffusion 
Coefficient. 
         




4.8 Effect of Combining Molecular Radius of Gyration and Shape Factors 
Then, inserting the A/B values from Table 4.12 along with the different radii (hydrodynamic 
and gyration) from Table 4.13 into equation (3.14), the diffusion coefficients for different 
cases/conditions are estimated and the results are summarized in Table 4.14. 
Table 4.14 Diffusion Coefficients using Different Radius and ξ / ξL Values 
       Case Diffusion Coefficient (cm2/sec) 
D Rg(0.77)+ξ+ξl(IIa)  1.7623E-09 
D Rg(1.732)+ξ+ξl(IIb)  3.964E-09 
D Rg(0.77)+ξL+ξ(IIIa)  1.7998E-09 
D Rg(1.732)+ξL+ξ(IIIb)  1.3214E-09 
Dexperimental 1.467E-09 






Figure 4.11  Diffusion coefficient comparison between experimental and DRg(0.77)+ξ+ξl(IIa)     
               The comparison of cumulative release curve of Dexperimental and D Rg(1.732)+ξ+ξl(IIb is 













Figure 4.12  Comparison of Diffusion coefficient of experimental and D Rg(1.732)+ξ+ξl(IIb . 







Figure 4.13  Comparison of Diffusion coefficient of experimental and DRg (0.77) +ξL+ξ (IIIa) The 





















CHAPTER 5                                                                                                        
DISCUSSION 
 
The DZE equation shows that Diffusion Coefficient can easily be estimated without the need 
of experimental work and still provide a very good approximation. The DZE demonstrates 
the effect of molecular shape as seen in Figure 5.1.   
 
 Figure 5.1 Comparison of Diffusion Coefficient using shape factors 
             The effect of the radius on the diffusion coefficient is as follows – 30% (Rg = 1.732 
R0) to + 58% (Rg = 0.77 R0) difference when compared with the experimental value as seen 









Figure 5.2 Comparison of Diffusion Coefficient 
           The effect of the integration of molecular shape and radius of gyration, used in the 
diffusion coefficient, affected the results from 90% to 270% when compared with the 










A combination of parameters such as DRg (1.732) +ξL+ξ (IIIb)) has a 90% accuracy against 
the experimental value as seen in Figure 5.3. 
 
 
Figure 5. 3 Comparison of Diffusion Coefficient using different molecular shape and 




However, when combining the effect of the hydrodynamic radius, Rh, with the modified 
shape factor, ξL, then a very close approximation to the experimental value is achieved as 
seen in figure 5.4.  
 
                
          




Although the DZE can be considered as an empirical approach, it still uses molecular 
descriptors that relate to the morphology and chemical parameters of the diffusing solute and 
the surrounding matrix. 
         One of the key aspects of this model is the use of group contribution and 
thermodynamic methods such as Joback, Yamada and Gunn, Pitzer and Williams and 
Landel. 
          The energy component, E*, is not particularly large which is in agreement to the 
findings of Vrentas and Vrentas(66) which contradicts the findings seen by HU(67). This could 
perhaps be due to the lack of a chemical affinity between the solute and the polymeric 

















 CHAPTER 6  
 CONCLUSIONS 
 
In US patent 5603947 [1], Wong et al. reported typical diffusion coefficient values of 
Nicotine patches that were experimentally determined to be between 10-8 to 10-9 cm2/sec. 
This is in agreement with the experimental and theoretical values obtained in this research.  
            The DZE modified equation (DZME) shows a small influence of the interaction 
between the solute and the polymeric structure which was indicated by Wang, Wu and Wang 
(68). DZME shows that molecular shape has a greater impact on the Diffusion Coefficient and 
this is in agreement with the findings of Reyner et al (69). 
             The combination of molecular size, defined as hydrodynamic and Gyration radius, 
Rh and Rg, along with molecular shape of the diffusing molecule, can influence the Diffusion 
Coefficient as reported by Zhimin (70) and De Kee et al (71) work.  
              The DZME shows a slight deviation from Chandler’s(72) Self Diffusion Coefficient 
models based on hard spheres and this should be expected since solute molecules should not 
be seen as hard spheres but more as small to large flexible coils as described by De 






Figure 6.1 De Gennes Molecular Representation 
Source: Reptation, http://en.wikipedia.org/wiki/Reptation. Accessed on December 7, 2014 
 
         where solute molecules will diffuse through a polymeric matrix on a reptation pattern 















Figure 6.2  De Gennes Molecular Reptation Pattern 
Source: Polymer Reptation, http://euler.phys.cmu.edu/widom/images/polymer_icon.gif.   
Retrieved on December 7, 2014. 
 
       Examining the results obtained when considering hydrodynamic radius, Rh, compared to 
the gyration radius, Rg, the results are close to the experimental values. This particular model 
shows that the Diffusion Coefficient can be influenced by the molecular shape and size, type 
of radius used.  
        The DZE proves that mathematical models can help and demonstrate key processes that 
can influence drug delivery (76). 
          Therefore, this work shows that the modified Duda Zelinsky equation can be used not 
only to obtain diffusion coefficients that are closer to the experimental value, but more 
importantly, it can be used as a screening methodology to help select the most suitable 
polymeric matrix for a particular solute that will provide the right Diffusion Coefficient that 





 FUTURE WORK 
 
Although this work shows that DZE is a good screening methodology, the following aspects 
could enhance this methodology: 
1. Physical properties selection protocol (PPSP) - 
The use of group contribution methods for the estimation of physical properties when 
the experimental data is missing or not readily available; this should be based on 
Aliphatic and Aromatic chemical structures. 
2. Expand from a singularity to a general model - 
Compare DZE with different solutes and polymeric matrices with experimental/  
literature data. 
3. Reptation Model evaluation - 
Evaluate the effect of DeGennes scaling reptation concept (74)  
D ~ M-2 c (2-υ)/ (1-3υ)  
4. Skin Penetration Effect - 
Evaluate the effect of incorporating DZE into the Guy-Potts skin penetration equation 
log KP  = -2.71 – 0.0061*Mw + 0.74 * log P (75-78) 
5. Permeation in Textiles -  
Evaluate the effect of incorporating the DZE into the modified Darcy’s equation 






Table A.1 shows the transdermal delivery systems that are presently available in the global 
market (up to 2014). 
 







name(s) Manufacturer Daily dose 
Frequency of 
application Type of system 























































  Climara® 
3 M Drug Delivery 
Systems, 
Northridge, CA, 



















be worn at 

















name(s) Manufacturer Daily dose 
Frequency of 






















uses a 28-day 
(four-week) 




















and lauryl lactate 
as inactive 
components 











Inc., Titusville, NJ, 
USA 
0.6 mg Once every three days Reservoir 
Lidocaine 234 Lidoderm® 
Endo 
Pharmaceuticals 











up to three 
patches, only 






















name(s) Manufacturer Daily dose 
Frequency of 





Pty Ltd, Baulkham 
Hills, NSW, 
Australia. 



















adhesives with a 
resinous cross-
linking agent to 
provide a 
continuous 
source of active 
ingredient 
  Nitrodisc® 
GD Searie, 
























1.0 mg of 
scopolami














Inc. A subsidiary 
of Watson 
Pharmaceuticals, 










nightly for 24 
hours, 
providing a 










hydroxide NF, to 
adjust pH, and 
purified water 








Ref.: Tanner, T. and Marks, R., Delivering drugs by the transdermal route: review and 
comment, Skin Research & Technology, Volume 14, Issue 3, pages 249–260, 2008 – 








TYPES OF TRANSDERMAL PATCHES 
Table A.2 shows the types of patches commercially available in the US and EU 
 












1. Estraderm Estradiol Membrane Postmenstrual 
syndrome 
2. Duragesic Fentanyl Reservoir Pain relief patch 
3. Transderm-Scop (Scopolamine)  Reservoir                              Motion sickness 
4. Alora Estradiol Matrix Postmenstrual 
Syndrome 
5. Climara Estradiol Matrix Postmenstrual 
Syndrome 
6. Androderm Testosterone Membrane Hypogonadism in 
males 
7. Captopress TTS Clonidine Membrane Hypertension 
8. Combipatch Estradiol Matrix Postmenstrual 
Syndrome 
9. Esclim Estradiol Matrix Harmone 
replacement 
therapy 
10. Deponit Nitroglycerine Drug in adhesive Angina Pectoris 
11. FemPatch Estradiol Matrix Postmenstrual 
syndrome 
12. Lidoderm Lidocaine Drug in adhesive Anesthetic 
13. Ortho Evra Estradiol Drug in adhesive Postmenstrual 
Syndrome 
14. Testoderm TTS Testosterone Reservoir Hypogonadism in 
males 
15. Habitrol Nicotine Drug in adhesive Smoking 
Cessation 


















16. Prostep Nicotine Reservoir Smoking 
Cessation 
17. Nicotrol Nicotine Drug in adhesive Smoking 
Cessation 
18. Vivelle Estradiol Reservoir Postmenstrual 
syndrome 
19. MatrifenR Fentanyl Reservoir Pain relief patch 
20. NuPatch 100 Diclofenac 
diethylamine 
Drug in adhesive Anti 
Inflammatory 
21. Nicoderm CQ Nicotine Drug in adhesive Smoking 
Cessation 
22. Vivelle-Dot Estradiol Reservoir Postmenstrual 
syndrome 
23. Minitran Nitroglycerine Drug in adhesive Angina Pectoris 
24. Nitrodisc Nitroglycerine Micro reservoir Angina Pectoris 
25. Nitrodur Nitroglycerine Matrix Angina Pectoris 
26. TransdermNitro Nitroglycerine Reservoir Angina Pectoris 
27. OxytrolR oxybutynin Matrix Overactive 
bladder 
28. Nuvelle TS Estradiol Drug in adhesive Harmone 
replacement 
therapy 
29. Fematrix Estrogen Matrix Postmenstrual 
syndrome 




Ref: TRANSDERMAL PATCHES: A RECENT APPROCH TO NEW DRUG DELIVERY 
SYSTEM, SONIA DHIMAN*, THAKUR GURJEET SINGH AND ASHISH KUMAR 







Summary of Release Kinetics 
Table C.1 shows a summary of the release kinetics and transport mechanisms of all 
commercially sold transdermal patches. 
Table C.1 - Summary of release kinetics and transport mechanisms of nondegradable 
polymer based delivery devices 













1 d Near 
linear 
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PDMS Intravaginal ring 
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TMC120 w/o Zero 
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 Table C.1 - Summary of release kinetics and transport mechanisms of nondegradable 
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Hydrogel Vitamin E ~3 h Biphasic Swelling 
HPMC with β- 
CD 



























Experimental Data Analysis 
This appendix the statistical analysis done for the validation of the data generated during the 
experimental phase. Experimental data for testing Transdermal Patches in Vitro by means of 
Franz Cells utilizing the procedures outlined by the United States Pharmacopeia (USP)(1 -2) 
and the FDA (3) . (See Tables D.1 and D.3).  
 Cell Bank D.1 – Raw Data 
Cum 
Release                   
Mt / Minf                   
Cell Bank 
1                   
Time, hrs. 
→ 0 1 2 3 4 5 6 7 23 
Cell # ↓                   
1 0 0.51 1.14 1.42 1.70 2.23 2.77 3.19 4.80 
2 0 0.48 1.21 1.52 1.84 2.14 2.85 3.13 4.61 
3 0 0.47 1.11 1.49 1.74 2.11 2.96 3.07 4.94 
4 0 0.55 1.08 1.38 1.57 2.34 2.69 3.39 4.42 







Figure D.1. Cell Bank 1 - Cumulative Release vs. Time 
 
Table D.2. Cell Bank 1 – Statistical Analysis 
Cell # R2 (Polynomial Fit) R2 (Linear Fit) 
1 0.9953 0.8656 
2 0.9898 0.8589 
3 0.9845 0.8844 
4 0.9832 0.7592 








Figure D.2. Cell Bank 1 - Cumulative Release vs. Time – Average Curve / Response 








Figure D.3. Cell Bank 1 –Confidence Interval Level Analysis (Individual and Sum Plots) 
             The 95 % Confidence Interval Level Analysis for the experimental data from Cell 
Bank 1 is uniform and with a narrow difference between data points indicating a robust 















Bank Cell 1 - Statistical Release Data
Box Plot
     
 
Figure D.4. Cell Bank 1 –Box Plot Analysis (Individual and Sum Plots) 
           The box plot analysis for the experimental data from Cell Bank 1 is uniform and with 
a narrow difference between data points indicating a robust statistical data set. 
 
Table D.3. Cell Bank 2 – Raw Data 
 
Cum 
Release                   
Mt / Minf                   
Cell Bank 
2                   
Time, 
hrs. → 0 1 2 3 4 5 6 7 23 
Cell # ↓                   
1 0 0.50 0.87 1.12 1.37 2.08 2.56 3.03 5.08 
2 0 0.54 0.85 1.06 1.46 1.95 2.66 3.11 4.88 
3 0 0.57 0.81 1.10 1.43 2.03 2.61 3.33 4.63 
4 0 0.53 0.85 1.12 1.48 2.11 2.53 3.49 4.91 








Figure D.5. Cell Bank 2 - Cumulative Release vs. Time 
Table D.4. Cell Bank 2 – Statistical Analysis 
Cell # R2 (Polynomial Fit) R2 (Linear Fit) 
1 0.9884 0.8872 
2 0.984 0.8596 
3 0.9752 0.8124 
4 0.9743 0.8283 






Release Time, hrs 
 
 
Figure D.6. Cell Bank 2 - Cumulative Release vs. Time – Average Curve / Response 












Interval Plot - Cell Bank 2
Number of Cells: 5
95% CI for the Mean




           Figure D.7. Cell Bank 2 –Confidence Interval Level Analysis (Individual and    




Release Time, hrs 
 
The 95 % Confidence Interval Level Analysis for the experimental data from Cell Bank 2 is 
uniform and with a narrow difference between data points indicating a robust statistical data 
set.  
          The box plot analysis for the experimental data from Cell Bank 2 is uniform and with a 








Figure D.8. Cell Bank 2 –Box Plot Analysis (Individual and Sum Plots) 
 
           In order to assess the statistical validity / cohesiveness of the data from the readings, 
one preferred option is using the Coefficient of Variation that can help determine the 
frequencies of the magnitudes of differences amongst the experimental values. The lower the 




“Coefficient of variation” 
In probability theory and statistics, the coefficient of variation (CV) is a standardized 
measure of dispersion of a probability distribution or frequency distribution. It is defined as 
the ratio of the standard deviation to the mean . It is also known as unitized risk or the 
variation coefficient. The absolute value of the CV is sometimes known as relative standard 
deviation (RSD), which is expressed as a percentage. 
Definition 
The coefficient of variation (CV) is defined as the ratio of the standard deviation to the 
mean : 
 
It shows the extent of variability in relation to mean of the population. 
            The coefficient of variation should be computed only for data measured on a ratio 
scale, as these are measurements that can only take non-negative values. The coefficient of 
variation may not have any meaning for data on an interval scale. Measurements that are log-
normally distributed exhibit stationary CV; in contrast, SD would vary depending on the 










Statistical Data Summary 
 
The Coefficient of Variance for Bank Cell 1 shows a very narrow distribution of 4.022 to 
6.413 which indicates results are substantive and valid with no major statistical deviations 
amongst all results. (See Table 5) 




1 2 3 4 5 6 7 23 
Average 0.499 1.130 1.430 1.720 2.248 2.796 3.240 4.732 
Standard 
Deviation 0.032 0.048 0.077 0.099 0.133 0.112 0.156 0.219 
Coefficient of 
Variation 6.413 4.241 5.381 5.773 5.899 4.022 4.811 4.625 
Number of Cells: 5 
The Coefficient of Variance for Bank Cell 1 shows a very narrow distribution of 2.915 to 
5.610 which indicates results are substantive and valid with no major statistical deviations 
amongst all results. (See Table 6) 




1 2 3 4 5 6 7 23 
Average 0.540 0.833 1.109 1.429 2.083 2.535 3.249 4.834 
Standard 
Deviation 0.028 0.035 0.032 0.045 0.106 0.127 0.182 0.185 
Coefficient of 
Variation 5.119 4.188 2.915 3.120 5.084 5.022 5.610 3.831 
 










The experimental data and statistical analysis from Cell Banks 1 and 2 show a good 
consistent response with a very narrow deviation and close Coefficient of Variation values 




Figure D.9. Cell Banks 1 and 2 – Cumulative Release vs. Time – Average Curve / Response 
Comparison 
 
         The statistical results from both Bank Cells are consistently equivalent to each other. 





Table D.7. Cell Banks 1 and 2 – Summary Statistical Analysis 
Bank Cell ID R2 (Polynomial Fit) 
 
R2 (Linear Fit) 
1 0.9944 0.8271 
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Molecular Shape Factor Calculations 
In order to evaluate the effect of the molecular shape, a series of calculations had to be 
performed based on the work of Dr. Jurs’ group at Pennsylvania State University in late 
1970’s to late 1980’s. They developed a software package named ADAPT that was capable 
to determine the molecular radius, among other parameters. However, trying to obtain and 
use the software became a challenge and with the assistance of Dr. C.M. Vrentas, who 
became one of the main users / adaptors for the work done in diffusion modelling, was able 
to locate one of its members, Dr. David T. Stanton. The author approached Dr. Stanton and 
explained the need to obtain access to the software. Dr. Stanton not only offered to assist but 
also performed all the necessary calculations that enable to complete the DZE model and 
research. The following pages are the summary of the results and the theoretical background 
of the ADAPT software done by Dr. David T. Stanton to whom the author is highly indebted 












Worklist ADAPT Structure ID Full Structure ID
Ionization 
State MAX-L/B MIN-L/B SHDW-1 SHDW-2 SHDW-3 SHDW-4 SHDW-5 SHDW-6
1 2-phenoxyethanol 2-phenoxyethanol Neutral 1.580 1.580 51.72 38 24.04 0.5224 0.5352 0.4906
2 Fentanyl Fentanyl Neutral 1.817 1.724 106.8 82 50.04 0.4748 0.5093 0.5267
3 Glycidate Glycidate (AM1) Anion 1.442 1.399 32.92 28.56 20.44 0.5144 0.476 0.4443
4 Glycidate2 Glycidate2 (DFT) Anion 1.452 1.306 32.88 28.04 19.8 0.5138 0.4673 0.44
5 N-hydroxymethyl-gly N-(hydroxymethyl)-glycine Neutral 1.510 1.507 36.08 31.48 20.32 0.5229 0.5161 0.4417
6 Nicotine Nicotine Neutral 1.452 1.313 49.6 51.12 34.96 0.4769 0.5112 0.4856
7 Scopolamine Scopolamine Neutral 1.570 1.570 76.08 70.04 49.04 0.5005 0.5559 0.5389
Note:  The structures were first oriented to align the first two principal moments of intertia
to the X and Y axes, respectively, before any of the shape calculations were performed.
MAX-L/B = the L/B ratio for the structure orientation that maximizes this ratio
MIN-L/B = the L/B ratio for the structure orientation that minimizes this ratio 
SHDW-1 = area projected onto the X-Y plane
SHDW-2 = area projected onto the X-Z plane
SHDW-3 = area projected onto the Y-Z plane
SHDW-4 = Standardized SHDW-1
SHDW-5 = Standardized SHDW-2
SHDW-6 = Standardized SHDW-3
The Standardized shadow areas (SHDW-4, SHDW-5, and SHDW-6) minimize the the size dependence of the shadow areas 
by
dividing the shadow area by the area of the box that encompasses the shadow for a given plane.  In other words, the 1st 
standardized




The original Rohrbaugh and Jurs paper used molecular mechanics to obtain the 3D atomic coordinates 
for the shadow areas.  The papers by Vrentras and Vrentras do not specific how the 3D coordinates 
were generated.  It's expected that as long as all the calculations are done using the same methods, the 
results will be consistent.  With that in mind, I've chosen to use semi -empirical quantum mechanical 
optimization (AM1) as is available in Spartan '08 (Wavefunction, Inc., ver. 1.1.0, Build 131)






Information received was ambiguous with regard to the position of the pyridine nitrogen.  
Decided to use SciFinder as a the primary reference

Nicotine○












The ionized form (glycinate) is an anion as shown:
Both the anion and the neutral form (glycine) will be used (just in case)
Hydroxymethyl glycinate (Sodium salt)○
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Molecular mechanics, MMFF force field
Total charge = Neutral (used Anion for glycidate)
Compute equilibrium conformer○
Semi-empirical, AM1
Total charge = 0 (used Anion for glycidate)
Compute equilibrium geometry○
The geometry obtained for glycidate was folded, with the hydroxyl hydrogen being strongly 
attracted to the anion.  In water this might not be a proper geometry, but I am not certain about 
the case of glycidate in the polymer if it exists as the anion in the polymer.
○
Spartan calculation sequence:
○ Copies the Glycidate structure to a new file named Glycidate2
Spartan conditions: Equlibrium geometry, DFT, B3LYP, 6-31G*, in water○
Decided to run a copy of the final glycidate AM1 structure at the ab initio level to see if the geometry 
changes at all

See Data Files Section○
Exported all seven of the structures from Spartan as individual Sybyl MOL2 files
Added appropriate file names (Spartan did not put proper structure file name in the exported 
MOL2 File).
○
Stored the files in a single Sybyl database○
Working directory:  ~/dat/Falcone/Polymer-diffusion/○
Imported the MOL2 files into Sybyl
Exported the Sybyl database as a single multi -structure MOL (Sybyl MOL) format file
Moved the MOL file to the Linux computer
Working directory: ~/dat/Falcone/Polymer-diffusion/adapt1○
Created a new ADAPT data area
Created a worklist including the seven structures○
Stored the structures in the ADAPT files
CURRENT OPERATING PARAMETERS
USE MAIN DESCRIPTOR AREA
USE WORKLIST
GRID DENSITY:    5
ORIENT WITH MOMENTS OF INERTIA
FIRST AREA WILL BE STORED IN LAN   1
SECOND AREA WILL BE STORED IN LAN   2
THIRD AREA WILL BE STORED IN LAN   3
AREA ONE STD. WILL BE STORED IN LAN   4
AREA TWO STD. WILL BE STORED IN LAN   5
AREA THREE STD. WILL BE STORED IN LAN   6
OUTPUT TO OUTPUT FILE
SHADOW parameters:○
Computed the SHADOW descriptors
   Lab Notes Page 2    
STRUCTURES WILL BE STORED IN INITIAL ORIENTATION
Note that the structures were stored in the initial orientation (oriented the first two principal 
moments on the X-Y axes).
○
CURRENT OPERATING PARAMETERS:
USE MAIN DESCRIPTOR AREA
USE WORKLIST
ANGLE FOR ROTATION:   1.0
MAXIMUM L/B RATIO IS SET FOR STORAGE
MIN. AREA L/B IS SET FOR STORAGE
DESCRIPTORS WILL BE STORED IN LANS :
7
8
OUTPUT TO OUTPUT FILE
LOVERB parameters:○




Exported the computed descriptors to a text file.  Moved the text file back to the PC and created an 
Excel spreadsheet

Forwarded the results and the Rohrbaugh and Jurs paper to R. Falcone by Email (19 -Jan-2010)
END
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